<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Trop Med Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Trop Med Infect Dis</journal-id><journal-id journal-id-type="publisher-id">tropicalmed</journal-id><journal-title-group><journal-title>Tropical Medicine and Infectious Disease</journal-title></journal-title-group><issn pub-type="epub">2414-6366</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998054</article-id><article-id pub-id-type="pmc">PMC11860281</article-id>
<article-id pub-id-type="doi">10.3390/tropicalmed10020050</article-id><article-id pub-id-type="publisher-id">tropicalmed-10-00050</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1642-306X</contrib-id><name><surname>Mazzeti</surname><given-names>Ana Lia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-tropicalmed-10-00050" ref-type="aff">1</xref><xref rid="c1-tropicalmed-10-00050" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>Karolina Ribeiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af2-tropicalmed-10-00050" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Boasquivis</surname><given-names>Patr&#x000ed;cia Ferreira</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-tropicalmed-10-00050" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Bahia</surname><given-names>Maria Terezinha</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-tropicalmed-10-00050" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0368-6090</contrib-id><name><surname>Mosqueira</surname><given-names>Vanessa Carla Furtado</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-tropicalmed-10-00050" ref-type="aff">4</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Zingales</surname><given-names>Bianca Silvana</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-tropicalmed-10-00050"><label>1</label>Laborat&#x000f3;rio Integrado de Imunoparasitologia e Farmacotoxicologia, Universidade do Estado de Minas Gerais, Unidade Acad&#x000ea;mica de Passos, Passos 37900-106, MG, Brazil</aff><aff id="af2-tropicalmed-10-00050"><label>2</label>Laborat&#x000f3;rio de Doen&#x000e7;as Parasit&#x000e1;rias, Escola de Medicina &#x00026; N&#x000fa;cleo de Pesquisas em Ci&#x000ea;ncias Biol&#x000f3;gicas, Universidade Federal de Ouro Preto, Campus Universit&#x000e1;rio Morro do Cruzeiro, Ouro Preto 35400-000, MG, Brazil; <email>krgbio@gmail.com</email> (K.R.G.); <email>mtbahia@ufop.edu.br</email> (M.T.B.)</aff><aff id="af3-tropicalmed-10-00050"><label>3</label>Diretoria Industrial, Funda&#x000e7;&#x000e3;o Ezequiel Dias, Belo Horizonte 30510-010, MG, Brazil; <email>patricia.boasquivis@funed.mg.gov.br</email></aff><aff id="af4-tropicalmed-10-00050"><label>4</label>Laboratory of Pharmaceutics and Nanotechnology, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil; <email>mosqueira@ufop.edu.br</email></aff><author-notes><corresp id="c1-tropicalmed-10-00050"><label>*</label>Correspondence: <email>ana.mazzeti@uemg.br</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>50</elocation-id><history><date date-type="received"><day>26</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>01</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Chagas disease, caused by <italic toggle="yes">Trypanosoma cruzi</italic>, remains a neglected tropical disease with limited and often suboptimal chemotherapeutic treatment options. The WHO recommends nifurtimox (NFX) for treating Chagas disease, which, although it is effective in the early stages of infection, has variable efficacy in the chronic phase and induces adverse effects that frequently compromise the continuity of the treatment. This study focused on the development and characterization of innovative lipid-based self-emulsifying drug delivery systems (SEDDSs) and poly(&#x003b5;-caprolactone) implants containing NFX. The SEDDS formulations modified the NFX release extent and rate. The implant characterization included thermal analysis, X-ray diffraction, thermo-optical analysis, and scanning electron microscopy, confirming the low interaction between NFX and the polymer. In vitro assays demonstrated the enhanced anti-<italic toggle="yes">T. cruzi</italic> activity of the NFX-SEDDS, with minimal cytotoxicity in mammalian cells. In vivo studies using <italic toggle="yes">T. cruzi</italic>-infected mice revealed that both formulations effectively suppressed parasitemia, achieving cure rates comparable to those of the standard oral NFX treatment. Additionally, the implants showed improved tolerability and sustained efficacy, delivering a prolonged effect equivalent to 40 oral doses. These findings highlight the potential of these innovative NFX formulations as promising alternatives for treating Chagas disease, particularly in the chronic phase, offering improved adherence and comparable efficacy to the existing therapies.</p></abstract><kwd-group><kwd>trypanosomiasis</kwd><kwd>nifurtimox</kwd><kwd>self-emulsifying drug delivery systems</kwd><kwd>poly(&#x003b5;-caprolactone)</kwd><kwd>implants</kwd></kwd-group><funding-group><award-group><funding-source>National Council for Scientific and Technological Development (CNPq)</funding-source><award-id>#313602/2019-0</award-id></award-group><award-group><funding-source>WHO</funding-source><award-id>A0790</award-id></award-group><award-group><funding-source>NANOBIOMG</funding-source><award-id>#00007-14</award-id><award-id>#40/11</award-id></award-group><award-group><funding-source>FAPEMIG</funding-source><award-id>APQ-02576-18</award-id></award-group><award-group><funding-source>the University of Minas Gerais State</funding-source><award-id>PQ/UEMG 06/2023&#x02014;ALM</award-id></award-group><funding-statement>This work was supported by National Council for Scientific and Technological Development (CNPq) grants to VCF Mosqueira (#313602/2019-0). A partial support is afforded by WHO-A0790 re-entry grant, the NANOBIOMG Network (#00007-14 and #40/11), FAPEMIG grants (APQ-02576-18), and the University of Minas Gerais State (Researcher Productivity Scholarship, PQ/UEMG 06/2023&#x02014;ALM).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-tropicalmed-10-00050"><title>1. Introduction</title><p>Chagas disease, caused by the protozoan <italic toggle="yes">Trypanosoma cruzi</italic> [<xref rid="B1-tropicalmed-10-00050" ref-type="bibr">1</xref>,<xref rid="B2-tropicalmed-10-00050" ref-type="bibr">2</xref>,<xref rid="B3-tropicalmed-10-00050" ref-type="bibr">3</xref>], is a neglected tropical disease affecting approximately 7 million people worldwide [<xref rid="B4-tropicalmed-10-00050" ref-type="bibr">4</xref>], with the highest burden in vulnerable regions of Latin America [<xref rid="B5-tropicalmed-10-00050" ref-type="bibr">5</xref>]. This life-threatening disease is very complex and involves a stage within the guts of hematophagous insects and other invertebrate hosts, with varied evolutionary extra- and intracellular forms of the protozoan and an ability to infect any type of nucleated human cell. Infective forms of <italic toggle="yes">T. cruzi</italic> are released in the feces and urine of infected Triatomine insects and gain access to the bloodstream of a human host through lesions in the skin or mucous membranes [<xref rid="B2-tropicalmed-10-00050" ref-type="bibr">2</xref>,<xref rid="B3-tropicalmed-10-00050" ref-type="bibr">3</xref>].</p><p>The two drugs recommended by the World Health Organization (WHO) for treating Chagas disease are the nitro-heterocyclic compounds benznidazole (IUPAC name: N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide) (BZN) and nifurtimox (NFX) (IUPAC name: (E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine) (<xref rid="tropicalmed-10-00050-f001" ref-type="fig">Figure 1</xref>). The precise mechanisms of action of these drugs have not been fully elucidated. Both act as prodrugs activated by <italic toggle="yes">T. cruzi</italic> nitroreductases to induce cytotoxic effects. NFX generates radical species that cause oxidative damage, including thiol depletion, DNA damage, and lipid peroxidation [<xref rid="B6-tropicalmed-10-00050" ref-type="bibr">6</xref>,<xref rid="B7-tropicalmed-10-00050" ref-type="bibr">7</xref>,<xref rid="B8-tropicalmed-10-00050" ref-type="bibr">8</xref>,<xref rid="B9-tropicalmed-10-00050" ref-type="bibr">9</xref>]. In contrast, BNZ forms reactive metabolites that alkylate DNA, lipids, and proteins. BNZ may also stimulate immune-mediated parasite killing by increasing the interferon-&#x003b3; levels due to inflammation. Additionally, BNZ exposure leads to extensive DNA unpacking in parasites and the upregulation of DNA repair proteins, suggesting a DNA-damage-based mechanism [<xref rid="B6-tropicalmed-10-00050" ref-type="bibr">6</xref>,<xref rid="B7-tropicalmed-10-00050" ref-type="bibr">7</xref>,<xref rid="B8-tropicalmed-10-00050" ref-type="bibr">8</xref>,<xref rid="B9-tropicalmed-10-00050" ref-type="bibr">9</xref>]. Both are used at high doses for long periods of treatment in Chagas disease. NFX is administered orally at 10&#x02013;15 mg/kg/day, divided into two or three doses, for 60 days during both the acute and chronic phases of <italic toggle="yes">T. cruzi</italic> infection [<xref rid="B10-tropicalmed-10-00050" ref-type="bibr">10</xref>,<xref rid="B11-tropicalmed-10-00050" ref-type="bibr">11</xref>].</p><p>NFX is also part of the first-line treatment for second-stage gambiense human African trypanosomiasis (HAT), also known as sleeping sickness, administered as part of a combination therapy with eflornithine. HAT is caused by <italic toggle="yes">Trypanosoma brucei</italic> and is considered a serious, neglected parasitic illness [<xref rid="B12-tropicalmed-10-00050" ref-type="bibr">12</xref>]. In the combined regimen, NFX is given orally three times daily for 10 days (15 mg/kg per day, every 8 h), while eflornithine is administered intravenously twice daily for 7 days (400 mg/kg per day, every 12 h) [<xref rid="B13-tropicalmed-10-00050" ref-type="bibr">13</xref>,<xref rid="B14-tropicalmed-10-00050" ref-type="bibr">14</xref>]. This combination therapy requires hospitalization, intensive nursing care, and a complex logistical network for drug transportation.</p><p>For Chagas disease, evidence suggests that treatment with BZN or NFX is effective during the early stages of infection. However, its benefit in the late chronic stages remains questionable due to its limited and variable efficacy [<xref rid="B11-tropicalmed-10-00050" ref-type="bibr">11</xref>,<xref rid="B15-tropicalmed-10-00050" ref-type="bibr">15</xref>,<xref rid="B16-tropicalmed-10-00050" ref-type="bibr">16</xref>]. Moreover, the prolonged treatment duration often results in adverse reactions, leading to poor adherence and high dropout rates [<xref rid="B17-tropicalmed-10-00050" ref-type="bibr">17</xref>]. Regarding NFX, common adverse effects include gastrointestinal symptoms such as nausea, vomiting, and anorexia, as well as central-nervous-system-related issues like insomnia, irritability, and disorientation. Less frequently reported side effects are headache, rash, myalgia, arthralgia, dizziness, vertigo, and mood changes. Severe but rare adverse effects include polyneuropathy, paresthesia, and peripheral neuritis [<xref rid="B17-tropicalmed-10-00050" ref-type="bibr">17</xref>,<xref rid="B18-tropicalmed-10-00050" ref-type="bibr">18</xref>]. However, when the treatment with one drug, BZN or NFX, must be discontinued, the other can be used as an alternative. Despite the large number of compounds that has been tested in vitro, few have demonstrated an ability to induce a parasitological cure or alter the disease progression in animal models, and even fewer have advanced to clinical trials [<xref rid="B19-tropicalmed-10-00050" ref-type="bibr">19</xref>]. Nitro compounds remain some of the most promising options in combating diseases caused by parasites of the <italic toggle="yes">Trypanosoma</italic> genus. NFX has been also investigated as a potential treatment for pediatric tumors, such as neuroblastoma [<xref rid="B20-tropicalmed-10-00050" ref-type="bibr">20</xref>,<xref rid="B21-tropicalmed-10-00050" ref-type="bibr">21</xref>,<xref rid="B22-tropicalmed-10-00050" ref-type="bibr">22</xref>], and it was patented for treating cancer and inhibiting angiogenesis [<xref rid="B23-tropicalmed-10-00050" ref-type="bibr">23</xref>].</p><p>Among the faster strategies for improving the efficacy in Chagas disease and HAT treatment, drug combination strategies and the development of new formulations containing nitro-heterocyclic drugs are envisaged [<xref rid="B24-tropicalmed-10-00050" ref-type="bibr">24</xref>,<xref rid="B25-tropicalmed-10-00050" ref-type="bibr">25</xref>]. NFX has biopharmaceutical limitations, such as poor physicochemical stability, low solubility, erratic bioavailability, and fast metabolization, with consequent fast elimination (a half-life of 3 h) [<xref rid="B26-tropicalmed-10-00050" ref-type="bibr">26</xref>]. NFX&#x02019;s solubility and dissolution rate limit its absorption [<xref rid="B27-tropicalmed-10-00050" ref-type="bibr">27</xref>,<xref rid="B28-tropicalmed-10-00050" ref-type="bibr">28</xref>]. The reformulation of NFX into a new dosage form may overcome these issues, but studies exploring this approach are scarce. Recently, our group has demonstrated that a self-emulsifying drug delivery system (SEDDS) provided advantages for dose adjustments to BZN with similar efficacy in an animal model [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>]. SEDDSs are stable anhydrous formulations that improve drug absorption via the lymphatic pathway, reduce first-pass metabolism, and consequently improve bioavailability [<xref rid="B30-tropicalmed-10-00050" ref-type="bibr">30</xref>,<xref rid="B31-tropicalmed-10-00050" ref-type="bibr">31</xref>,<xref rid="B32-tropicalmed-10-00050" ref-type="bibr">32</xref>]. Thus, high plasma concentrations and reduced metabolization rates may be achieved. Additionally, BZN poly(&#x003b5;-caprolactone) (PCL) implants improved the pharmacokinetic profile compared with that using classical BZN tablets in healthy and infected animals [<xref rid="B33-tropicalmed-10-00050" ref-type="bibr">33</xref>]. The main advantage of implant devices is the drug being released for an extended time&#x02014;for example, for months&#x02014;through the diffusion or degradation of its matrix by esterases in the body. PCL is a safe, stable, and low-cost biodegradable polymer [<xref rid="B34-tropicalmed-10-00050" ref-type="bibr">34</xref>,<xref rid="B35-tropicalmed-10-00050" ref-type="bibr">35</xref>,<xref rid="B36-tropicalmed-10-00050" ref-type="bibr">36</xref>] and is thus advantageous as a raw material for developing formulations for tropical neglected diseases that affect poor populations. Furthermore, implants in prolonged treatment are beneficial for maintaining doses and body exposure without the interruptions to treatment that occur frequently in patients suffering from Chagas disease. Therefore, these issues are the main challenges in NFX chemotherapy in Chagas disease, which could be circumvented by reformulating NFX.</p><p>This study aims to investigate the potential of implants and SEDDS to modify the efficacy of NFX. A lipid-based formulation for oral administration (the SEDDS) and a polymeric subcutaneous implant formulation for long-term release were developed, characterized, and tested in a murine infection model of <italic toggle="yes">T. cruzi</italic>. Both could be beneficial for the long treatment durations in this challenging antiparasitic chemotherapy, improving patient compliance.</p></sec><sec id="sec2-tropicalmed-10-00050"><title>2. Materials and Methods</title><sec id="sec2dot1-tropicalmed-10-00050"><title>2.1. Drugs and Materials</title><p>NFX was donated by the Drug for Neglected Diseases initiative (DND<italic toggle="yes">i</italic>). Cyclophosphamide (<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine-2-oxide (Genuxal) was purchased from Baxter (Baxter Oncology GmbH, Bielefeld, Germany, Germany). HPLC-grade acetonitrile, acetone, ethanol, and dimethyl sulfoxide (DMSO) were provided by Tedia<sup>&#x000ae;</sup> (Rio de Janeiro, Brazil). Miglyol<sup>&#x000ae;</sup>810N (medium-chain triglycerides) was provided by Sasol GmbH (Sasol Germany GmbH, Brunsb&#x000fc;ttel, Germany). Lecithin containing 70% phosphatidylcholine (Lipoid<sup>&#x000ae;</sup>S75) was provided by Lipoid GmbH (Frigenstrasse, Germany). Food-grade soy and sunflower oil was purchased from Liza<sup>&#x000ae;</sup> (Cargill, Uberlandia, Brazil). Lipoid S75<sup>&#x000ae;</sup> containing approximately 75% phosphatidylcholine was purchased from Lipoid GmbH (Ludwigshafen am Rhein, Germany). Tween<sup>&#x000ae;</sup>80, sodium phosphate monobasic, sodium hydroxide, hydrochloric acid, <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylacetamide (DMA), and <italic toggle="yes">N</italic>-methyl pyrrolidone (NMP) were purchased from Vetec (Vetec Qu&#x000ed;mica Fina Ltda, Xer&#x000e9;m, RJ, Brazil). Labrasol<sup>&#x000ae;</sup> and Capryol 90<sup>&#x000ae;</sup> were purchased from Gattefoss&#x000e9; (Saint Priest, France), and Cremophor<sup>&#x000ae;</sup>EL was provided by BASF (Ludwigshafen am Rhein, Germany). Ultra-purified water was obtained using the Symplicity<sup>&#x000ae;</sup>185 system (Millipore, Bedford, MA, USA). Trypsin, fetal bovine serum (FBS), l-glutamine, penicillin/streptomycin, and Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM) as the cell culture medium were purchased from Sigma-Aldrich Co (St Louis, MO, USA). The poly-&#x003b5;-caprolactone polymer (PCL; Mw 65,000 and Mn 42,500 g/mol, &#x000d0; 1.529 at 25 &#x000b0;C) was purchased from Sigma (Sigma-Aldrich Co., St. Louis, MO, USA).</p></sec><sec id="sec2dot2-tropicalmed-10-00050"><title>2.2. The Chromatographic Conditions and Determination of Nifurtimox&#x02019;s Solubility and Log P </title><p>NFX quantification was performed using a Waters Alliance e2695 High-Performance Liquid Chromatograph (HPLC) with a Waters 2489 UV detector. The analysis employed a C18 Phenomenex<sup>&#x000ae;</sup> Gemini column (150 &#x000d7; 4.6 mm, 5 &#x003bc;m) and a C18 Phenomenex<sup>&#x000ae;</sup> pre-column (2 mm &#x000d7; 4.6 mm, 3 &#x003bc;m). The mobile phase consisted of an acetonitrile/water mixture (80:20 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>), using isocratic elution at a flow rate of 0.80 mL/min, an injection volume of 25 &#x003bc;L, and a column temperature of 25&#x000b0;C. Detection was performed at 400 nm, the maximal absorption wavelength, which was chosen after a diode array detector (HPLC-DAD) scan from 210 to 500 nm. The NFX standard (purity &#x0003e; 98%) was obtained from Sigma-Aldrich&#x02122;. The selectivity, specificity, linearity, precision, accuracy, detection limit, and quantification limit parameters were evaluated.</p><p>To improve the solubility of NFX in the analytical samples, many solvents were tested&#x02014;for example, chloroform, dimethylacetamide, ethanol, hexane, methanol, <italic toggle="yes">N</italic>-methyl pyrrolidone, tetrahydrofuran, <italic toggle="yes">n</italic>-octanol, ethyl acetate, acetone, and benzyl alcohol. Solubility studies were also conducted in aqueous media, ultrapure water, and phosphate buffer saline (PBS). An excess of the drug (20 mg) was added to 1 mL of each solvent and incubated in a water bath at 37 &#x000b0;C for 48 h under magnetic agitation (SPLabor Multi-position Magnetic Stirrer with Heater). The mixtures were then centrifuged at 10,000 rpm for 20 min. The supernatant was carefully collected (100 &#x003bc;L) and filtered through 0.45 &#x003bc;m filters (Millipore). A 10 &#x003bc;L aliquot of the filtrate was diluted in 990 &#x003bc;L of acetonitrile for subsequent analysis using HPLC-UV/Vis.</p><p>The partition coefficient of NFX was determined using the moderate agitation method, validated for low-aqueous-solubility products [<xref rid="B37-tropicalmed-10-00050" ref-type="bibr">37</xref>]. <italic toggle="yes">N</italic>-octanol was used as the organic phase, and distilled water or phosphate-buffered saline (PBS) was used as the aqueous phase. The concentration of the drug in each phase was determined using HPLC-UV using the method described above. The experiment was performed in triplicate. The partition coefficient was expressed as the base 10 logarithm of the ratio between the drug concentration in the <italic toggle="yes">n</italic>-octanol and in the aqueous phases [log <italic toggle="yes">P</italic>].</p></sec><sec id="sec2dot3-tropicalmed-10-00050"><title>2.3. Preparation and Characterization of the Nifurtimox Self-Emulsifying Delivery System (NFX-SEDDS)</title><p>The SEDDS was developed based on data on NFX&#x02019;s solubility available in <xref rid="app1-tropicalmed-10-00050" ref-type="app">Supplementary Materials</xref>. The final composition was Miglyol 810N:Capryol 90:Lipoid S75:Labrasol:<italic toggle="yes">N</italic>-methyl pyrrolidone (NMP) (30:15:20:15:20) (% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). The SEDDS formulation was based on a BZN-loaded SEDDS previously developed, which was prepared under stirring and heating, as described by Mazzeti et al., 2020 [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>]. To characterize the SEDDS, the following parameters were evaluated: the mean globule hydrodynamic diameter, the polydispersity index, and the zeta potential determined using Zetasizer PN3702 equipment (Malvern Instruments, Malvern, UK) as previously reported [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>,<xref rid="B38-tropicalmed-10-00050" ref-type="bibr">38</xref>]. The NFX content in the formulation was evaluated using HPLC-UV/Vis according to the conditions validated above. Centrifugation tests were also performed to evaluate the stability of the emulsions formed after the dilution of the SEDDS in water. Furthermore, the effect of storage time on the physical stability of the SEDDS was also evaluated following a method described previously [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot4-tropicalmed-10-00050"><title>2.4. The Nifurtimox Release Kinetics In Vitro</title><p>The release kinetics of NFX from the NFX-SEDDS were evaluated using two different media, simulated gastric fluid (pH 1.2 &#x000b1; 0.05) and simulated intestinal fluid (pH 7.5 &#x000b1; 0.05), prepared according to the United States Pharmacopeia [<xref rid="B39-tropicalmed-10-00050" ref-type="bibr">39</xref>] and previously described in detail [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>,<xref rid="B40-tropicalmed-10-00050" ref-type="bibr">40</xref>]. Pre-emulsified NFX-SEDDS formulations (1:10) were placed into cellulose dialysis membranes (6.4 mm, SpectraPor<sup>&#x000ae;</sup>, Spectrum Labs, East Longmeadow, MA, USA) that had been pre-hydrated in Milli-Q water for 24 h. The amount of NFX incorporated was adjusted to the sink conditions (approximately 10% of the maximum solubility in the respective media). The dialysis membranes were sealed using nylon threads and immersed in vessels containing either the simulated gastric or intestinal fluid. The experiments were conducted at 37 &#x000b0;C under constant agitation. Samples were collected in the bulk media at predetermined time intervals (0, 5, 15, 30, 60, 120, 180, 240, and 300 min) and quantified using HPLC-UV. The removed sample volume in the external media was replaced with fresh medium to maintain the conditions [<xref rid="B41-tropicalmed-10-00050" ref-type="bibr">41</xref>]. For comparative purposes, the same procedure was applied using coarse dispersions of NFX prepared in a 0.5% methylcellulose solution, which were also placed into the dialysis membranes under identical conditions. The experiments were performed in triplicate, as described by Zhang et al. [<xref rid="B41-tropicalmed-10-00050" ref-type="bibr">41</xref>].</p><p>The release and dissolution kinetics of NFX from the SEDDS were calculated based on experimental data using the mathematical models demonstrating the best fitting, determined by the coefficient of determination (R2). The first-order, Higuchi, and Weibull models were applied using DDSolver 1.0 Add-in software for Excel [<xref rid="B42-tropicalmed-10-00050" ref-type="bibr">42</xref>]. Experimental data on the in vitro release studies are reported as the means &#x000b1; standard deviations.</p></sec><sec id="sec2dot5-tropicalmed-10-00050"><title>2.5. In Vitro Cytotoxicity to Host Cells</title><p>The cytotoxicity of the NFX-SEDDS was determined in H9c2 cells (American Type Culture Collection, ATCC: CRL 1446), a cardiomyoblast lineage from rats. The cells were seeded at 1 &#x000d7; 10<sup>3</sup> cells/well into 96-well plates with 100 &#x003bc;L of media and incubated for 24 h. Afterward, the cells were treated with free NFX (powder of the raw material) prepared from DMSO stock solutions and diluted in culture medium, ensuring a final DMSO concentration below 0.5% to prevent host cell toxicity. The additional treatments included the NFX-SEDDS or an equivalent amount of a blank-SEDDS being emulsified and diluted in the culture medium [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>]. Eight successive serial dilutions (1:2) were made, starting with 1000 &#x003bc;M of the drug. A cell toxicity control was established using eight 1:2 serial dilutions of DMSO, starting at a concentration of 20% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). The cell viability was measured after 72 h using the Resazurin colorimetric assay [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>,<xref rid="B43-tropicalmed-10-00050" ref-type="bibr">43</xref>]. A reduction of more than 30% in the cell viability was considered cytotoxic [<xref rid="B44-tropicalmed-10-00050" ref-type="bibr">44</xref>].</p></sec><sec id="sec2dot6-tropicalmed-10-00050"><title>2.6. The Anti-<underline>T</underline>. <underline>cruzi</underline> Activity of the Nifurtmox-SEDDS (Amastigotes)</title><p>The in vitro anti-<italic toggle="yes">T. cruzi</italic> activity assays were performed using H9c2 cells infected by trypomastigotes of the <italic toggle="yes">T. cruzi</italic> Y strain, which were obtained from the supernatant of the infected cells [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>,<xref rid="B45-tropicalmed-10-00050" ref-type="bibr">45</xref>]. In 24-well culture plates covered with 13 mm cover slips, at 1 &#x000d7; 10<sup>4</sup> cells/well, after 24 h, the cells were infected with <italic toggle="yes">T. cruzi</italic> trypomastigotes at a 20:1 ratio of the parasites to the host cells. After 24 h, the cells were treated with either free NFX (prepared from DMSO stock solutions and diluted in culture medium), the NFX-SEDDS, or an equivalent amount of a blank-SEDDS, both of which were emulsified and diluted in the culture medium [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>]. The highest concentration was 10 &#x003bc;M of NFX for all groups, and subsequently, seven serial dilutions (1:2) were performed. After 72 h of incubation at 37 &#x000b0;C and 5% CO<sub>2</sub>, the cells were washed and fixed with methanol and stained with Giemsa. Anti-<italic toggle="yes">T. cruzi</italic> activity was calculated based on the inhibition of cell infection by amastigote forms, compared to that with the untreated control using a microscopic analysis, counting at least 200 cells per sample. All of the experiments were performed in duplicate, with at least two replicates. The IC<sub>50</sub> values were calculated using CalcuSyn 2.1 software (Biosoft, Kington, UK).</p></sec><sec id="sec2dot7-tropicalmed-10-00050"><title>2.7. Preparation and Characterization of the Polymeric Implants Containing Nifurtimox (NFX-PCL)</title><p>Initially, the NFX implants were produced using different concentrations of PCL (50 or 75) via the casting method [<xref rid="B33-tropicalmed-10-00050" ref-type="bibr">33</xref>]. Solid semicircular implants were molded in glass molds. The doses of NFX incorporated into the PCL polymer were based on the standardized oral dose for mice (50 mg/kg), assuming an average body weight of 25 g. Specifically, NFX (25, 37.5, or 50 mg) was weighed into the glass molds, followed by the addition of 100 &#x000b5;L of acetone and PCL. This amount incorporated 20-, 30-, and 40-fold the daily dose of NFX per mouse into the PCL implants. The mixture was stirred and heated at 65 &#x000b0;C in a water bath under 50 rpm agitation until complete dissolution. Afterward, the acetone was evaporated under heating at 65 &#x000b0;C, allowing the implant to solidify in a chemical hood. Residual solvents were removed under reduced pressure in a desiccator for 96 h. Blank implants (without NFX) were also prepared using the same procedure. The final implants were semicircular in shape and had a diameter of 10 mm [<xref rid="B33-tropicalmed-10-00050" ref-type="bibr">33</xref>].</p><p>The thermal behaviors of NFX, the polymeric implants containing NFX (NFX-PCL), and the physical mixtures of PCL and NFX were determined using Differential Scanning Calorimetry (DSC) and thermo-optical analysis (TOA). The DSC analyses were performed using a Mettler Toledo DSC 822e instrument, using indium and zinc standards. Approximately 2 mg was prepared in sealed aluminum pans. The samples were analyzed in the 25&#x02013;200 &#x000b0;C temperature range, with a heating rate of 10&#x000b0;C/min, under a nitrogen atmosphere, and at a flow rate of 50 mL/min. The thermo-optical analysis was performed using a Mettler Toledo FP900, with an FP90 processor and an FP82 hot stage. Images were captured using a Leica DM4000B optical microscope with a 10&#x000d7; objective (C Plan), providing a total magnification of 100&#x000d7;. For the NFX analysis, the temperature range was set between 175 and 195 &#x000b0;C, with a heating rate of 2 &#x000b0;C/min. For the physical mixtures of PCL and NTX, the analyses were conducted in two temperature ranges: the first between 55 and 75 &#x000b0;C and the second between 155 and 185 &#x000b0;C.</p><p>All of the X-ray diffraction (XRD) analyses were conducted using a Rigaku Miniflex 300 system. The diffractograms were collected under the following settings&#x02014;an angle range of 2&#x000b0; to 45&#x000b0; 2&#x003b8;, a voltage of 30 kV, a current of 10 mA, 0.02&#x000b0; increments, and a scan rate of 5&#x000b0;/min&#x02014;using a high-speed D-Tex Ultra detector.</p><p>The scanning electron microscopy (SEM) analyses were performed on a JEOL JCM-6000 system. Samples were prepared on carbon double-sided tape and fixed onto aluminum stubs. The pure NFX samples were gold-coated using a Denton Vacuum Desk V system, whereas the implant samples were not coated. Images were captured under varying fields and conditions.</p></sec><sec id="sec2dot8-tropicalmed-10-00050"><title>2.8. Anti-<underline>T</underline>. <underline>cruzi</underline> Efficacy Studies in Mice</title><p>Female Swiss mice (18&#x02013;24 g) were housed at the animal facility (CCA) of the Federal University of Ouro Preto, Brazil, under a controlled temperature (22 &#x000b1; 2 &#x000b0;C) and 12-h light/dark cycles. The animals had free access to water and food. All of the procedures complied with the Ethical Principles of Animal Experimentation (COBEA) and were approved by the UFOP Ethics Committee under protocols 2014/56 and 2015/54.</p><p>To determine the efficacy of the new formulations in an experimental murine model of infection, we inoculated the female mice via the intraperitoneal route with 5000 trypomastigotes of the Y strain of <italic toggle="yes">T. cruzi</italic>. This strain exhibits partial sensitivity to BNZ and NFX, achieving a 47% cure rate in mice treated orally from the 4th day post-infection for 20 consecutive days with 100 mg/kg of either BZN or NFX [<xref rid="B46-tropicalmed-10-00050" ref-type="bibr">46</xref>]. The treatments, via gavage or subcutaneous surgery for the implants, started on the 4th day of infection. The surgery was performed in anesthetized animals as per Mazzeti et al. [<xref rid="B33-tropicalmed-10-00050" ref-type="bibr">33</xref>]. After the implantation surgery, the animals were maintained in individual cages with access to food and water ad libitum. Subsequently, the animals were monitored for any signs of infection at the operative site or upon discomfort or distress. Any mice presenting with such signs were immediately euthanized. Complete healing at the site of surgery was observed in all animals. We also treated a control group of mice via the oral route with 50 mg/kg/day of NFX suspended in 0.5% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) methylcellulose and administered via gavage. The experimental groups are shown in the schematic experimental design in <xref rid="tropicalmed-10-00050-f002" ref-type="fig">Figure 2</xref>.</p><p>The animals were examined at least once a day to observe mortality and changes in clinical signs: appearance (twisting, piloerection, dirty eyes), pain (torsion, spasm), and behavior changes (withdrawal, vocalization, scratching, reluctance to move, irritability, anorexia, abnormal posture, ataxia).</p><p>The efficacy of the treatment was estimated by detecting parasites through fresh blood examination (FBE), using qPCR, and detecting mortality before and after the immunosuppression cycles, determined following the protocol previously described [<xref rid="B47-tropicalmed-10-00050" ref-type="bibr">47</xref>]. Briefly, mortality was checked daily until 30 days after the treatment. Fresh blood examination was performed daily to estimate the parasitemia during and up to 30 days after the end of the treatment, according to the Brener method [<xref rid="B48-tropicalmed-10-00050" ref-type="bibr">48</xref>]. Animals with negative results in the fresh blood examination were immunosuppressed using 50 mg/kg/day of cyclophosphamide (Baxter Oncology, Bielefeld, Germany) via the intraperitoneal route according to 3 cycles of 4 consecutive daily doses, with an interval of 3 days between each cycle. Parasitemia was checked daily during and up to 10 days after the end of the immunosuppression cycles (<xref rid="tropicalmed-10-00050-f002" ref-type="fig">Figure 2</xref>).</p><p>The blood qPCR analyses were performed 30 and 180 days after the end of the treatment in samples from mice with negative fresh blood examination results. The Promega Wizard genomic DNA purification kit (United States) was used to extract the genomic DNA from 200 &#x003bc;L blood samples, according to the manufacturer&#x02019;s instructions. The PCR analyses were performed using the primers TCZ-F (5=-GCTCTTGCCCACAMGGGTGC-3=, where M indicates A or C) and TCZ-R (5=-CCAAGCAGCGGATAGTTCAGG-3=), as described by [<xref rid="B49-tropicalmed-10-00050" ref-type="bibr">49</xref>]. The presence of <italic toggle="yes">T. cruzi</italic> in the blood samples was evaluated by amplifying a 195 bp tandem repeat in the genomic DNA [<xref rid="B49-tropicalmed-10-00050" ref-type="bibr">49</xref>]. The murine TNF-&#x003b1; gene sequence was amplified separately using the primers TNF-5241 (5=-TCCCTCTCATCAGTTCTATGGCCCA-3=) and TNF-5411 (5=-CAGCAAGCATCTATGCACTTAGACCCC-3=) [<xref rid="B49-tropicalmed-10-00050" ref-type="bibr">49</xref>]. For the reactions, 2 &#x000b5;L of template DNA (25 ng/&#x000b5;L), 10 &#x000b5;M of the primers, and 5 &#x000b5;L of Sybr-Green PCR Master Mix were used at a total volume of 10 &#x000b5;L. The amplifications were performed on a 7500 Fast Real-Time PCR System with 40 cycles at 94 &#x000b0;C for 15 s, followed by fluorescence data collection at 64.3 &#x000b0;C for 1 min. A melting curve analysis was conducted from 60 &#x000b0;C to 95 &#x000b0;C at 0.3 &#x000b0;C/s [<xref rid="B47-tropicalmed-10-00050" ref-type="bibr">47</xref>]. All of the samples were analyzed in duplicate, and negative samples and reagent controls were processed in parallel in each assay. Animals that showed negative results in all of the tests were considered cured.</p></sec><sec id="sec2dot9-tropicalmed-10-00050"><title>2.9. Biochemical Toxicity Analysis</title><p>The toxicity of the treatments was evaluated through the hepatic enzyme dosages in the mouse serum collected on the last day of the treatment. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined using a colorimetric assay using an autoanalyzer (Wiener Lab model CM200&#x02014;kinetic analysis) and a commercial Bioclin<sup>&#x000ae;</sup> kit according to the manufacturer&#x02019;s instructions [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot10-tropicalmed-10-00050"><title>2.10. Statistical Analysis</title><p>Statistical treatment of the data was carried out using Graph Pad Prisma 5.01 statistical software (GraphPad Software Inc., San Diego, CA, USA). The results were expressed as the mean&#x02009; &#x000b1; &#x02009;standard deviation. Parametric data were analyzed using Student&#x02019;s <italic toggle="yes">t</italic>-test and nonparametric data using the Mann&#x02013;Whitney test for the toxicity analysis. Statistical significance was established with 95% confidence intervals and <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-tropicalmed-10-00050"><title>3. Results</title><sec id="sec3dot1-tropicalmed-10-00050"><title>3.1. Nifurtimox Characterization</title><p>Determination of the apparent solubility of NFX in the different solvents was performed using HPLC/UV at 400 nm, with a retention time of approximately 2.3 min, using an acetonitrile/water (80:20) mobile phase. The parameters of the selectivity, specificity, linearity, precision, accuracy, limit of detection, and quantification were in accordance with the Guide of the International Conference on Harmonization [<xref rid="B50-tropicalmed-10-00050" ref-type="bibr">50</xref>]. The solubility of NFX in the different solvents is shown in <xref rid="tropicalmed-10-00050-t001" ref-type="table">Table 1</xref>. This test indicated that NFX is insoluble in water, with <italic toggle="yes">N</italic>-methyl pyrrolidone (NMP) being the most suitable solvent (90.85 mg/mL).</p><p>The partition coefficient provides information on molecules&#x02019; lipophilicity, which is closely related to their ability to passively cross biological membranes. The log <italic toggle="yes">P</italic> values for NFX in <italic toggle="yes">n</italic>-octanol/water were 0.87 &#x000b1; 0.05 and 0.96 &#x000b1; 0.07 in n-octanol/PBS. An in silico analysis using ALOGPS and Swiss ADME estimated log <italic toggle="yes">P</italic> values for NFX of 0.25 and 0.54, respectively. Log <italic toggle="yes">P</italic> values below 1.72 indicate low membrane permeability [<xref rid="B52-tropicalmed-10-00050" ref-type="bibr">52</xref>], suggesting that NFX likely exhibits a limited ability to permeate membranes. Considering the experimental low apparent solubility and log <italic toggle="yes">P</italic> results, following the Biopharmaceutics Classification System (BCS), NFX can be classified as class IV, i.e., a low-solubility and low-permeability drug.</p></sec><sec id="sec3dot2-tropicalmed-10-00050"><title>3.2. Preparation and Characterization of the NFX-SEDDS</title><p>The SEDDS formulations self-emulsified immediately after their dilution in water. However, the droplets exhibited a broad size dispersion, as shown in <xref rid="tropicalmed-10-00050-t002" ref-type="table">Table 2</xref>. NFX incorporation into the SEDDS significantly increased the droplet size and polydispersity (<italic toggle="yes">p</italic> &#x0003c; 0.05) of the formulation. No significant effect of NFX on the zeta potential was evidenced. This result suggests NFX&#x02019;s incorporation into the oily core of the emulsions, shielded by non-ionic surfactants like Labrasol.</p><p>When the blank-SEDDS formulations were emulsified in Milli-Q water (at a 1:10 ratio), nanoemulsions were formed. After centrifugation, no signs of creaming or phase separation were observed, indicating the stability of the nanoemulsions after their dispersion in water [<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>,<xref rid="B53-tropicalmed-10-00050" ref-type="bibr">53</xref>]. The physicochemical characteristics of the formulations were also evaluated monthly during their storage for six months. No NFX precipitate was detected in the anhydrous mixture during the evaluated period, and after emulsification, the original physical appearance of the formulations was maintained.</p><p>The physicochemical stability of the anhydrous SEDDS formulations enabled in vitro drug release studies comparing the NFX-SEDDS with a coarse suspension of NFX in 0.5% methylcellulose water (free NFX). NFX&#x02019;s apparent solubility was first assessed in simulated gastric fluid and simulated intestinal fluid, measuring 0.094 &#x000b1; 0.01 mg/mL and 0.089 &#x000b1; 0.01 mg/mL, respectively.</p><p>The dissolution profile, analyzed under sink conditions and quantified via HPLC-UV/Vis, revealed a faster drug release from the coarse suspension of NFX than that from the NFX-SEDDS in both gastric and intestinal fluids at up to 300 min. Previous reports show the complete dissolution of NFX from tablets in less than 120 min [<xref rid="B28-tropicalmed-10-00050" ref-type="bibr">28</xref>]. The NFX-SEDDS showed consistent NFX release regardless of the pH, highlighting its potential for controlled release. The NFX release from coarse suspension was slower in intestinal media compared to gastric media (<xref rid="tropicalmed-10-00050-f003" ref-type="fig">Figure 3</xref>).</p><p>In the simulated gastric fluid, 50% of the NFX was released from the SEDDS after 5 h. In contrast, in the same period, almost 80% of the NFX was released from the coarse suspension, indicating that the SEDDS retained the drug inside the droplets for longer times in the gastric medium. Faster NFX release in the intestinal medium is observed for the coarse suspension compared with that for the SEDDS (<xref rid="tropicalmed-10-00050-f003" ref-type="fig">Figure 3</xref>). Thus, the SEDDS formulations slow down the NFX fraction released in alkaline conditions, with more potential to activate lymphatic transport and circumvent the first-pass metabolism in the liver. None of the formulations achieved 100% release of the NFX during the evaluated period, confirming its classification as a BCS class IV drug.</p><p>The NFX release experimental data were mathematically modelized according to the first-order, Higuchi, and Weibull models because they provided the best fit for all of the formulations tested in vitro. The values of the release constants (K<sub>1</sub>, K<sub>h</sub> and &#x003b1;, &#x003b2;) are shown, and the goodness of fit for each model was evaluated using statistical criteria, including the coefficient of determination (R2) and the Model Selection Criterion (MSC). The data were acquired for the NFX-SEDDS and the coarse suspension of NFX in order to compare the dissolution in the simulated gastric and intestinal fluid.</p><p>No statistical difference was observed among the SEDDS formulations at both pHs (SGF and SIF) in the first 120 min, in opposition to what occurred for the NFX suspensions. Thus, the incorporation of NFX into lipid droplets reduces the effects of pH on the release kinetics. The release constants in <xref rid="tropicalmed-10-00050-t003" ref-type="table">Table 3</xref> show that the SEDDS reduces the NFX release rate compared with that with the coarse suspensions. The first-order and Higuchi models describes better the experimental data for SEDDS. Weibull mathematical model was better to describe the release data of the NFX suspensions. A significant difference (<italic toggle="yes">p</italic> &#x0003c; 0.05) was observed in the time required to release 75% of the NFX between the SEDDS and the suspensions. In the simulated intestinal fluid, the SEDDS excipients influenced the Weibull parameter &#x003b2;, indicating that the release curve had a sigmoidal profile (&#x003b2; &#x0003e; 1).</p></sec><sec id="sec3dot3-tropicalmed-10-00050"><title>3.3. In Vitro Cytotoxicity and Anti-<underline>T</underline>. <underline>cruzi</underline> Activity of the NFX-SEDDS</title><p>After characterizing the physicochemical properties, stability, and drug release profiles of the SEDDS formulations, cytotoxicity tests were conducted to assess their effects on mammalian cells (host cells). From the dose&#x02013;response curves, the 50% cytotoxicity concentrations (CC<sub>50</sub>) for the NFX and NFX-SEDDS were determined to exceed 30 &#x000b5;M for the H9c2 cells. Only non-toxic concentrations were used in the anti-<italic toggle="yes">T. cruzi</italic> activity experiments. The dose&#x02013;response curves, evaluated in the H9c2 cells infected with the Y strain, of the free NFX and the NFX-SEDDS were similar, indicating that the formulation did not alter the drug&#x02019;s activity. The blank-SEDDS showed no inhibitory effect on infection. The IC<sub>50</sub> and IC<sub>90</sub> values for the free NFX were 0.72 &#x000b1; 0.15 &#x000b5;M and 6.88 &#x000b1; 4.77 &#x000b5;M, respectively, comparable to those of the NFX-SEDDS, which were 0.71 &#x000b1; 0.12 &#x000b5;M and 4.37 &#x000b1; 1.44 &#x000b5;M (<xref rid="tropicalmed-10-00050-t004" ref-type="table">Table 4</xref>). The selectivity indices (SIs), calculated as the CC<sub>50</sub>/IC<sub>50</sub> ratio, for the free NFX and the NFX-SEDDS were both greater than 45.</p></sec><sec id="sec3dot4-tropicalmed-10-00050"><title>3.4. Characterization of the Polymeric Implants Containing Nifurtimox (NFX-PCL)</title><p>NFX is a yellow to orange-yellow, odorless, crystalline powder [<xref rid="B27-tropicalmed-10-00050" ref-type="bibr">27</xref>]. The crystallographic data obtained in this study (<xref rid="tropicalmed-10-00050-f004" ref-type="fig">Figure 4</xref>B) confirm the crystalline nature of the NFX, demonstrating that the sample used consisted of a single crystal form, closely resembling the theoretical profile stored in the Cambridge Structural Database under the code &#x0201c;JAHPEN&#x0201d; (qui<sup>2</sup> = 1.8014) as previously reported [<xref rid="B54-tropicalmed-10-00050" ref-type="bibr">54</xref>]. The main (most intense) diffraction peaks were observed at angular positions of 14.575&#x000b0;, 17.041&#x000b0;, and 20.757&#x000b0; 2&#x003b8;.</p><p>Scanning electron microscopy (SEM) confirmed the crystalline nature of the sample, revealing a heterogeneous morphology that included both block- and plate-like particles of varying sizes, indicating that the sample comprised particles with a similarly diverse size distribution (<xref rid="tropicalmed-10-00050-f005" ref-type="fig">Figure 5</xref>).</p><p>The thermal profile of NFX was evaluated using Differential Scanning Calorimetry (DSC) (<xref rid="tropicalmed-10-00050-f006" ref-type="fig">Figure 6</xref>) and thermo-optical analysis (TOA) (<xref rid="tropicalmed-10-00050-f007" ref-type="fig">Figure 7</xref>). DSC revealed a single endothermic event corresponding to the NFX melting, occurring between 182.5 &#x000b0;C and 188.8 &#x000b0;C with a peak at 185.3 &#x000b0;C and an enthalpy of &#x02212;109.04 J/g (<xref rid="tropicalmed-10-00050-f006" ref-type="fig">Figure 6</xref>). The observation of a single melting event corroborates the X-ray diffraction (XRD) analysis, demonstrating that the sample contains a single crystalline phase. The TOA results showed slight variation, with fusion starting at 179.5 &#x000b0;C (<xref rid="tropicalmed-10-00050-f007" ref-type="fig">Figure 7</xref>). At 181.5 &#x000b0;C, it was already possible to observe the total fusion of the particles in the sample. These differences can be attributed to the distinct analytical conditions of each method. The melting range, 180&#x02013;182 &#x000b0;C, was consistent with data from the literature [<xref rid="B27-tropicalmed-10-00050" ref-type="bibr">27</xref>,<xref rid="B55-tropicalmed-10-00050" ref-type="bibr">55</xref>].</p><p><xref rid="tropicalmed-10-00050-f004" ref-type="fig">Figure 4</xref>A illustrates an overlay of an X-ray diffractogram of the NFX-PCL implant with that of pure NFX, highlighting the main diffraction peaks at 14.575&#x000b0;, 17.041&#x000b0;, and 20.757&#x000b0; 2&#x003b8;. <xref rid="tropicalmed-10-00050-f004" ref-type="fig">Figure 4</xref>B further shows an overlay with a diffractogram of the blank-PCL implant (without the drug). This analysis reveals that all of the diffraction peaks detected in the NFX-PCL implant corresponded directly to those observed in the separate analyses. This indicates that following the preparation of the implant, both the drug and the polymer maintained their crystalline and semicrystalline states, respectively, without chemical reactions or strong physical interactions. Therefore, under the analytical conditions employed, these results suggest that the method of implant preparation did not induce a polymorphic transition in the NFX, nor did it lead to its transformation into an amorphous solid state.</p><p>The SEM analyses further corroborate the results obtained using XRD, demonstrating that after the implant preparation, the drug remained in its crystalline state, dispersed within the polymer matrix. <xref rid="tropicalmed-10-00050-f008" ref-type="fig">Figure 8</xref>A&#x02013;C show scanning electron micrographs of the pure PCL implant (without the drug), where its porosity is visible, without the presence of defined crystalline structures. In contrast, <xref rid="tropicalmed-10-00050-f008" ref-type="fig">Figure 8</xref>D&#x02013;F display micrographs of the NFX-PCL implant, which also exhibits a porous structure. However, in these images (indicated by the red arrows), defined particles with a distinct morphology, absent from the pure PCL implant, can be observed and are likely attributed to intact NFX crystals.</p><p>Although the XRD and SEM analyses show that both the PCL and NFX retain their structures when they are combined in implant form, the DSC analyses indicate a certain degree of interaction between these components. <xref rid="tropicalmed-10-00050-f006" ref-type="fig">Figure 6</xref> presents the DSC curve of the NFX-PCL implant overlaid with the DSC curves obtained for the pure NFX and the blank-PCL implant. The DSC curve of the NFX-PCL implant shows two endothermic events. In the first event, corresponding to the melting of PCL, no variation in the melting range, peak temperature, or expected enthalpy was observed compared to the melting event in the DSC curve for the blank-PCL implant. The second event on the NFX-PCL&#x02019;s DSC curve can be attributed to the melting of the NFX within the implant. Observing this melting event confirms the XRD results, indicating that the drug remains in its crystalline state after implant preparation. However, this event is shifted and broadened, occurring between 164.9 &#x000b0;C and 184.3 &#x000b0;C with a peak at 177.5 &#x000b0;C. Furthermore, the enthalpy of this event was lower than expected: representing 40% of the formulation, the expected enthalpy of the NFX in the implant would be approximately &#x02212;43 J/g. However, the observed value was &#x02212;25.4 J/g, suggesting an interaction between the drug and the polymeric matrix.</p><p>To determine whether the changes in enthalpy observed in the DSC analysis were due to interactions between the substances, a TOA of the pure NFX and the NFX plus PCL mixture was conducted. In <xref rid="tropicalmed-10-00050-f009" ref-type="fig">Figure 9</xref>, the TOA of the NFX plus PCL mixture shows the polymer melting between 60 &#x000b0;C and 66 &#x000b0;C. At 155 &#x000b0;C, the NFX particles began to be redistributed in the melted polymer. Small particles dissolved first, indicating partial solubility of the drug in the molten polymer matrix, suggesting a physical, rather than a chemical, interaction. The larger drug particles began to melt at 179.5 &#x000b0;C and fully fused at 181.5 &#x000b0;C, similar to the pure NFX. The TOA results align with the DSC findings, where the fusion range of the NFX remained unchanged but the enthalpy was reduced, possibly due to partial solubilization of the drug into the PCL polymer.</p></sec><sec id="sec3dot5-tropicalmed-10-00050"><title>3.5. Anti-<underline>T</underline>. <underline>cruzi</underline> Efficacy of the SEDDS and the PCL Implants Containing Nifurtimox</title><p>To evaluate the treatment efficacy, Swiss mice were intraperitoneally inoculated with the partially benznidazole-sensitive Y strain of <italic toggle="yes">T. cruzi</italic>, and the treatments began on the fourth day post-infection, administered orally (via gavage) or through subcutaneous implantation of the drug-loaded devices. Post-surgical monitoring showed no signs of infection, discomfort, or distress, and all surgical sites healed completely. This approach allowed for a controlled evaluation of treatment effectiveness. All of the treatments with NFX successfully prevented mortality, which is otherwise observed in 100% of untreated infected animals.</p><p>The animals treated with either the free NFX or NFX formulations exhibited no changes in their clinical signs, appearance, or behavior or indications of pain. The infected mice treated with the blank-SEDDS or the blank-PCL implants showed outcomes similar to those for the untreated group, with no suppression of parasitemia or prevention of mortality. All of the treatments with NFX successfully prevented mortality, which is otherwise observed in 100% of untreated infected animals.</p><p>The SEDDS formulations demonstrated a similar in vivo efficacy to that of free NFX (<italic toggle="yes">p</italic> &#x0003e; 0.05) in reducing parasitemia in the <italic toggle="yes">T. cruzi</italic>-infected mice. Immunosuppression and qPCR confirmed cure rates of 28.6% for the NFX-SEDDS, highlighting its therapeutic potential compared to that of free NFX at the same dose (<xref rid="tropicalmed-10-00050-t005" ref-type="table">Table 5</xref>).</p><p>Initially, implants containing 50 or 75 mg of PCL and 25 mg of NFX (as the oral treatment with 50 mg/kg/day for 20 days) were evaluated in terms of their drug release (<xref rid="tropicalmed-10-00050-t005" ref-type="table">Table 5</xref>). Both formulations effectively suppressed parasitemia, but the 75 mg PCL implant (the NFX-PCL implant for 20 days) provided more sustained suppression, delaying parasitemia reactivation. The mice that received the 75 mg PCL implants (the NFX-PCL implant for 20 days) showed reactivation at 25 &#x000b1; 11.45 days, while the 50 mg PCL group experienced reactivation at 10.67 &#x000b1; 8.85 days. Oral treatment with 50 mg/kg of free NFX for 20 days resulted in parasitemia reactivation after 24.67 &#x000b1; 4.14 days. Increasing the NFX dosage in the implant to 50 mg of NFX + 75 mg of PCL (the NFX-PCL implant for 40 days) reduced the parasitemia reactivation to 20%, with no reactivation in the mice treated orally for 40 days. Administering oral NFX (50 mg/kg/day) for 10 days, followed by using a 37.5 mg NFX + 75 mg PCL implant (NFX-PCL implant for 30 days), resulted in parasitemia suppression in 2 &#x000b1; 1 days.</p><p>The cure rates varied by the administration route and duration. Oral NFX for 40 days cured 42.9% of the mice, similarly to the 40% cure rate for the NFX-PCL implant for 40 days. Shorter treatment durations resulted in lower cure rates for all of the NFX treatments and dosage forms (<xref rid="tropicalmed-10-00050-t005" ref-type="table">Table 5</xref>). The efficacy in this mice model is time- and dose-dependent, and the higher the duration of treatment, the higher the efficacy.</p><p>Liver enzyme levels, specifically AST and ALT, were measured in the serum of the animals on the final day of treatment. The levels of AST and ALT in the infected untreated control groups were assessed on the 15th day post-infection, prior to mortality caused by the Y strain of <italic toggle="yes">T. cruzi</italic>. <xref rid="tropicalmed-10-00050-f010" ref-type="fig">Figure 10</xref> presents the hepatic enzyme levels in the animals treated with different formulations of NFX. All treatments significantly reduced their AST and ALT levels compared to those in the untreated infected animals, indicating a decrease in tissue damage, which may be related to a reduction in the parasite load in the hepatic tissues.</p><p><xref rid="tropicalmed-10-00050-f011" ref-type="fig">Figure 11</xref> presents a schematic representation of the NFX delivery systems. Panel A illustrates the NFX-SEDDS, where NFX molecules were incorporated into micelles stabilized by phospholipids and the non-ionic surfactant Labrasol. This structure facilitates drug solubilization and potentially enhances bioavailability. Panel B shows the NFX-PCL implants, depicting the drug dispersed within the polymeric matrix. These innovative formulations aim to enhance NFX&#x02019;s solubility, bioavailability, and sustained release for improved therapeutic efficacy.</p></sec></sec><sec sec-type="discussion" id="sec4-tropicalmed-10-00050"><title>4. Discussion</title><p>Although NFX is one of the only two drugs available for the treatment of Chagas disease and used for HAT treatment, few details about the physicochemical characterization of this active pharmaceutical ingredient (API) are available [<xref rid="B27-tropicalmed-10-00050" ref-type="bibr">27</xref>]. The results of this study provide new insights into the development of innovative formulations of NFX for the treatment of Chagas disease. This is particularly significant given the limitations of the current therapies, which include low efficacy in the chronic phase of infection and significant adverse effects that hinder patient adherence [<xref rid="B18-tropicalmed-10-00050" ref-type="bibr">18</xref>,<xref rid="B56-tropicalmed-10-00050" ref-type="bibr">56</xref>]. Two formulations, a lipid-based self-emulsifying drug delivery system (SEDDS) and poly(&#x003b5;-caprolactone) (PCL) implants, were investigated for their potential to address these biopharmaceutical issues.</p><p>In the solubility tests, NFX demonstrated high solubility in NMP, a water-miscible, aprotic solvent, approved for use in the solubilization of drugs for oral and topical administration [<xref rid="B57-tropicalmed-10-00050" ref-type="bibr">57</xref>]. This solvent is useful for the solubilization of nitrofurans in assays in vitro and in vivo. Based on its water solubility and log <italic toggle="yes">P</italic> results, NFX can be classified as a BCS class IV drug, exhibiting low solubility and low permeability. These are critical and challenging physicochemical factors to consider in the development of new pharmaceutical formulations. In contrast, Kasim and co-authors estimated NFX&#x02019;s cLog P and solubility in water (33 mg/mL) and categorized the substance into class III (high-solubility and low-permeability) [<xref rid="B51-tropicalmed-10-00050" ref-type="bibr">51</xref>]. Our result in the present work differs greatly. In addition, NFX has previously been categorized as class II (low-solubility, high-permeability) and class IV (low-solubility, low-permeability) [<xref rid="B27-tropicalmed-10-00050" ref-type="bibr">27</xref>]. The contradictions observed may reflect the source of the data, the crystal forms, and the experimental and quantification methods used.</p><p>The NFX sample used in this study consisted of a single crystalline phase [<xref rid="B27-tropicalmed-10-00050" ref-type="bibr">27</xref>,<xref rid="B57-tropicalmed-10-00050" ref-type="bibr">57</xref>]. NFX&#x02019;s thermal characteristics observed in this study also correspond to those described by Moroni et al. (2023), who reported a melting peak at 181.8 &#x000b0;C in their DSC analysis and 178 &#x000b0;C in their thermo-optical analysis [<xref rid="B27-tropicalmed-10-00050" ref-type="bibr">27</xref>].</p><p>In vitro release tests are crucial for estimating the amount of the drug released when it is in contact with various physiological fluids via oral administration. The characterization of the SEDDS formulations revealed the improved dispersibility of NFX in the SEDDS after colloidal dispersion in water. The SEDDS maintains a consistent release rate across pH variations, a critical factor in overcoming the variable gastrointestinal environment, since the bioavailability of NFX is diet-dependent and erratic [<xref rid="B26-tropicalmed-10-00050" ref-type="bibr">26</xref>,<xref rid="B28-tropicalmed-10-00050" ref-type="bibr">28</xref>]. However, a slower release was observed, indicating that the SEDDS may retain NFX in the alkaline media inside nanodroplets. This may activate the lymphatic transport through the intestinal membrane, bypassing the first-pass metabolism [<xref rid="B58-tropicalmed-10-00050" ref-type="bibr">58</xref>,<xref rid="B59-tropicalmed-10-00050" ref-type="bibr">59</xref>]. If this absorption mechanism occurs, it may have effects on the elimination rate and eventually on efficacy. This point merits further investigation in future studies. The in vitro release studies helped correlate the percentage of the drug solubilized with its availability for absorption in vivo. However, the correlation between in vitro and in vivo assays is often weak due to the limitations of in vitro experiments, particularly in replicating the complexity of the gastrointestinal tract. In the case of SEDDS formulations, not only dispersion but also intestinal transit and lipid digestion by gastric and pancreatic lipases play a significant role in maintaining a drug in its solubilized form [<xref rid="B60-tropicalmed-10-00050" ref-type="bibr">60</xref>].</p><p>The cytotoxicity assays demonstrated that the NFX-SEDDS formulation was non-toxic at therapeutic concentrations, with its selectivity indices comparable to or better than those of free NFX. The anti-<italic toggle="yes">T. cruzi</italic> activity was preserved in the NFX-SEDDS, with the IC<sub>50</sub> values remaining within the expected ranges. This highlights the potential of these formulations to maintain or even enhance this drug&#x02019;s efficacy while reducing its systemic toxicity. These findings emphasize the importance of maintaining drug efficacy while minimizing host toxicity and consequently diminishing the general side effects for Chagas disease patients. Another advantage of the SEDDS formulation is the possibility of personalized dosing and administration in liquid form, which would facilitate treatment in pediatrics [<xref rid="B28-tropicalmed-10-00050" ref-type="bibr">28</xref>,<xref rid="B29-tropicalmed-10-00050" ref-type="bibr">29</xref>,<xref rid="B61-tropicalmed-10-00050" ref-type="bibr">61</xref>].</p><p>The characterization of the NFX-PCL implant indicates that NFX retains its crystalline structure within the implant, which is relevant from the perspective of its pharmacokinetic properties. Although the thermal analyses indicate that some degree of physical interaction occurs between the polymer and the drug&#x02014;likely due to the partial solubilization of nifurtimox in the polymer matrix&#x02014;it should be noted that this effect is observed under extreme temperature conditions. Nevertheless, these results suggest the presence of a physical, rather than a chemical, interaction between NFX and PCL. Possible chemical interactions, which could lead to the formation of potential drug degradation products, should still be evaluated in long-term stability studies. These minor physical interactions suggested some degree of solubilization, which might influence the NFX&#x02019;s release kinetics.</p><p>In vivo studies further evidenced the clinical potential of these formulations. The NFX-SEDDS provided parasitemia suppression comparable to that of the administration of free NFX. The NFX-PCL implants demonstrated sustained release over extended periods (20 days), potentially improving the patient adherence and treatment outcomes, as has already been demonstrated using benznidazole implants [<xref rid="B33-tropicalmed-10-00050" ref-type="bibr">33</xref>]. Although the cure rates were similar between the oral and implant formulations in mice model, the implants&#x02019; convenience and ability to maintain therapeutic levels for extended durations represent a significant advantage, especially for chronic-phase patients. Chagas disease is predominantly treated during the chronic phase, a stage where the parasite&#x02019;s replication slows and the symptoms often progress to severe cardiac or gastrointestinal complications. Treatment during this phase presents significant challenges, particularly related to patient adherence [<xref rid="B62-tropicalmed-10-00050" ref-type="bibr">62</xref>,<xref rid="B63-tropicalmed-10-00050" ref-type="bibr">63</xref>].</p><p>Regarding the toxicological profile of the formulations, the potential for toxicity to be induced by the formulation excipients, and the high NFX content incorporated into the implants, we evaluated the hepatic damage during treatment. The levels of the hepatic enzymes AST and ALT were measured in the serum of the animals on the last day of treatment. All treatments significantly reduced their AST and ALT levels in comparison to those in untreated infected animals. Furthermore, treatment with the various formulations, even over prolonged periods, did not interfere significantly with enzyme levels. This finding suggests treatment safety, potentially related to a reduction in the parasitic load in the liver [<xref rid="B64-tropicalmed-10-00050" ref-type="bibr">64</xref>]. In addition, a recent study showed the excellent biocompatibility and minimal cytotoxicity of PCL. PCL scaffolds implanted into male Wistar rats caused no signs of inflammation, tissue damage, or systemic toxicity [<xref rid="B65-tropicalmed-10-00050" ref-type="bibr">65</xref>]. These results underscore its potential for biomedical applications, including implantable drug delivery systems.</p><p>NFX faces significant limitations that necessitate the development of novel formulations. As a BCS class IV drug, its low solubility and permeability severely restrict its bioavailability and therapeutic efficacy [<xref rid="B24-tropicalmed-10-00050" ref-type="bibr">24</xref>]. Additionally, concerns related to its toxicity, narrow safety margin, and high interpatient variability in absorption further complicate its clinical application [<xref rid="B24-tropicalmed-10-00050" ref-type="bibr">24</xref>,<xref rid="B61-tropicalmed-10-00050" ref-type="bibr">61</xref>]. Previous strategies to enhance NFX delivery, including nanocarriers such as liposomes and polymeric nanoparticles, have shown potential in improving its solubility and protecting the drug from degradation under physiological conditions [<xref rid="B24-tropicalmed-10-00050" ref-type="bibr">24</xref>]. However, these approaches are hindered by challenges such as complex manufacturing processes, stability concerns, and difficulties in scaling up production. Clinical studies evaluating the biopharmaceutical characteristics of NFX tablets underscore the urgent need for strategies to enhance its dissolution and bioavailability [<xref rid="B61-tropicalmed-10-00050" ref-type="bibr">61</xref>]. Innovative formulations, including PCL implants and optimized SEDDSs, as investigated in this study, address these challenges by offering improved solubility, sustained release profiles, and better therapeutic outcomes, effectively overcoming the limitations of the conventional NFX delivery methods.</p></sec><sec sec-type="conclusions" id="sec5-tropicalmed-10-00050"><title>5. Conclusions</title><p>This study highlights the significant potential of NFX-SEDDSs and NFX-PCL implants as innovative drug delivery systems for Chagas disease, addressing the major limitations of the current treatments. The SEDDS formulations improved the drug&#x02019;s solubility and dispersibility in gastrointestinal fluid and reduced its systemic toxicity. These lipid-based systems have the potential to improve lymphatic absorption and reduce the first-pass metabolism, a notable advantage in maintaining therapeutic concentrations. The characterization of the implants confirmed the retention of NFX in its crystalline state, with minor physical interactions, which could enhance release kinetics without compromising stability. The sustained-release property of the implants offers a promising alternative for long-term therapy, being particularly suitable for chronic-phase Chagas disease, where patient adherence is critical. The use of a biocompatible polymer, such as PCL, minimizes the local and systemic toxicity while maintaining an efficacy comparable to that of the standard oral regimens. This approach aligns with the growing interest in new formulation strategies for neglected tropical diseases.</p><p>Future research should expand the tests with these formulations into chronic infection models and evaluate their applicability in strains with different susceptibility profiles. Additionally, long-term stability studies and pharmacokinetic modeling are essential to fully characterize the clinical potential of these systems. Combining pharmaceutical innovation with practical treatment solutions offers a path to improving patient outcomes and addressing the global health burden of Chagas disease. These findings also open new avenues for adapting similar technologies to other nitro-heterocyclic drugs used in the management of trypanosomatid-based infections, further broadening their therapeutic impact.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are also grateful to FINEP&#x02019;s financial support for improving the research infrastructure of UFOP, particularly its animal (CCA) and Cipharma/EF&#x02019;s multi-use facilities (UFOP FINEP 0367/2018).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-tropicalmed-10-00050"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/tropicalmed10020050/s1">https://www.mdpi.com/article/10.3390/tropicalmed10020050/s1</uri>, Table S1: Solubility of nifurtimox in different SEDDS excipients.</p><supplementary-material id="tropicalmed-10-00050-s001" position="float" content-type="local-data"><media xlink:href="tropicalmed-10-00050-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: A.L.M., M.T.B. and V.C.F.M. Methodology and formal analysis: A.L.M., K.R.G., P.F.B., M.T.B. and V.C.F.M. Investigation: A.L.M., K.R.G., P.F.B., M.T.B. and V.C.F.M. Resources: M.T.B. and V.C.F.M. Data curation: A.L.M., M.T.B. and V.C.F.M. Writing&#x02014;original draft preparation: A.L.M. Writing&#x02014;review and editing: A.L.M., P.F.B., M.T.B. and V.C.F.M. Visualization: A.L.M., M.T.B. and V.C.F.M. Supervision: M.T.B. and V.C.F.M. Project administration and funding acquisition: M.T.B. and V.C.F.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All procedures complied with the Ethical Principles of Animal Experimentation (COBEA) and were approved by the UFOP Ethics Committee under protocols 2014/56 and 2015/54.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-tropicalmed-10-00050" ref-type="app">Supplementary Material</xref>. Further inquiries can be directed to the corresponding authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-tropicalmed-10-00050"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chagas</surname><given-names>C.</given-names></name>
</person-group><article-title>Nova Tripanozomiaze Humana: Estudos Sobre a Morfolojia e o Ciclo Evolutivo Do Schizotrypanum Cruzi n. Gen., n. Sp., Ajente Etiolojico de Nova Entidade Morbida Do Homem</article-title><source>Mem. Inst. Oswaldo Cruz</source><year>1909</year><volume>1</volume><fpage>159</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1590/S0074-02761909000200008</pub-id></element-citation></ref><ref id="B2-tropicalmed-10-00050"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;n-Escolano</surname><given-names>J.</given-names></name>
<name><surname>Mar&#x000ed;n</surname><given-names>C.</given-names></name>
<name><surname>Rosales</surname><given-names>M.J.</given-names></name>
<name><surname>Tsaousis</surname><given-names>A.D.</given-names></name>
<name><surname>Medina-Carmona</surname><given-names>E.</given-names></name>
<name><surname>Mart&#x000ed;n-Escolano</surname><given-names>R.</given-names></name>
</person-group><article-title>An Updated View of the <italic toggle="yes">Trypanosoma Cruzi</italic> Life Cycle: Intervention Points for an Effective Treatment</article-title><source>ACS Infect. Dis.</source><year>2022</year><volume>8</volume><fpage>1107</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.2c00123</pub-id><pub-id pub-id-type="pmid">35652513</pub-id>
</element-citation></ref><ref id="B3-tropicalmed-10-00050"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zuma</surname><given-names>A.A.</given-names></name>
<name><surname>Dos Santos Barrias</surname><given-names>E.</given-names></name>
<name><surname>De Souza</surname><given-names>W.</given-names></name>
</person-group><article-title>Basic Biology of Trypanosoma Cruzi</article-title><source>Curr. Pharm. Des.</source><year>2021</year><volume>27</volume><fpage>1671</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.2174/1381612826999201203213527</pub-id><pub-id pub-id-type="pmid">33272165</pub-id>
</element-citation></ref><ref id="B4-tropicalmed-10-00050"><label>4.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Chagas Disease (Also Known as American Trypanosomiasis)</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-09-02">(accessed on 2 September 2022)</date-in-citation></element-citation></ref><ref id="B5-tropicalmed-10-00050"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lidani</surname><given-names>K.C.F.</given-names></name>
<name><surname>Andrade</surname><given-names>F.A.</given-names></name>
<name><surname>Bavia</surname><given-names>L.</given-names></name>
<name><surname>Damasceno</surname><given-names>F.S.</given-names></name>
<name><surname>Beltrame</surname><given-names>M.H.</given-names></name>
<name><surname>Messias-Reason</surname><given-names>I.J.</given-names></name>
<name><surname>Sandri</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Chagas Disease: From Discovery to a Worldwide Health Problem</article-title><source>Front. Public Health</source><year>2019</year><volume>7</volume><elocation-id>166</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2019.00166</pub-id><pub-id pub-id-type="pmid">31312626</pub-id>
</element-citation></ref><ref id="B6-tropicalmed-10-00050"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilkinson</surname><given-names>S.R.</given-names></name>
<name><surname>Kelly</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Trypanocidal Drugs: Mechanisms, Resistance and New Targets</article-title><source>Expert Rev. Mol. Med.</source><year>2009</year><volume>11</volume><fpage>e31</fpage><pub-id pub-id-type="doi">10.1017/S1462399409001252</pub-id><pub-id pub-id-type="pmid">19863838</pub-id>
</element-citation></ref><ref id="B7-tropicalmed-10-00050"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patterson</surname><given-names>S.</given-names></name>
<name><surname>Fairlamb</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Current and Future Prospects of Nitro-Compounds as Drugs for Trypanosomiasis and Leishmaniasis</article-title><source>Curr. Med. Chem.</source><year>2019</year><volume>26</volume><fpage>4454</fpage><lpage>4475</lpage><pub-id pub-id-type="doi">10.2174/0929867325666180426164352</pub-id><pub-id pub-id-type="pmid">29701144</pub-id>
</element-citation></ref><ref id="B8-tropicalmed-10-00050"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maya</surname><given-names>J.D.</given-names></name>
<name><surname>Cassels</surname><given-names>B.K.</given-names></name>
<name><surname>Iturriaga-V&#x000e1;squez</surname><given-names>P.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.</given-names></name>
<name><surname>Fa&#x000fa;ndez</surname><given-names>M.</given-names></name>
<name><surname>Galanti</surname><given-names>N.</given-names></name>
<name><surname>Ferreira</surname><given-names>A.</given-names></name>
<name><surname>Morello</surname><given-names>A.</given-names></name>
</person-group><article-title>Mode of Action of Natural and Synthetic Drugs against Trypanosoma Cruzi and Their Interaction with the Mammalian Host</article-title><source>Comp. Biochem. Physiol. Part A Mol. Integr. Physiol.</source><year>2007</year><volume>146</volume><fpage>601</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2006.03.004</pub-id><pub-id pub-id-type="pmid">16626984</pub-id>
</element-citation></ref><ref id="B9-tropicalmed-10-00050"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raj&#x000e3;o</surname><given-names>M.A.</given-names></name>
<name><surname>Furtado</surname><given-names>C.</given-names></name>
<name><surname>Alves</surname><given-names>C.L.</given-names></name>
<name><surname>Passos-Silva</surname><given-names>D.G.</given-names></name>
<name><surname>de Moura</surname><given-names>M.B.</given-names></name>
<name><surname>Schamber-Reis</surname><given-names>B.L.</given-names></name>
<name><surname>Kunrath-Lima</surname><given-names>M.</given-names></name>
<name><surname>Zuma</surname><given-names>A.A.</given-names></name>
<name><surname>Vieira-da-Rocha</surname><given-names>J.P.</given-names></name>
<name><surname>Garcia</surname><given-names>J.B.F.</given-names></name>
<etal/>
</person-group><article-title>Unveiling Benznidazole&#x02019;s Mechanism of Action through Overexpression of DNA Repair Proteins in Trypanosoma Cruzi</article-title><source>Environ. Mol. Mutagen.</source><year>2014</year><volume>55</volume><fpage>309</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1002/em.21839</pub-id><pub-id pub-id-type="pmid">24347026</pub-id>
</element-citation></ref><ref id="B10-tropicalmed-10-00050"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>PAHO/WHO</collab>
</person-group><source>Guidelines for the Diagnosis and Treatment of Chagas Disease</source><publisher-name>PAHO</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2019</year><isbn>978-92-75-12043-9</isbn></element-citation></ref><ref id="B11-tropicalmed-10-00050"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakare</surname><given-names>R.</given-names></name>
<name><surname>Dasgupta</surname><given-names>A.</given-names></name>
<name><surname>Chopra</surname><given-names>S.</given-names></name>
</person-group><article-title>Update on Nifurtimox for Treatment of Chagas Disease</article-title><source>Drugs Today</source><year>2021</year><volume>57</volume><fpage>251</fpage><pub-id pub-id-type="doi">10.1358/dot.2021.57.4.3251712</pub-id><pub-id pub-id-type="pmid">33851689</pub-id>
</element-citation></ref><ref id="B12-tropicalmed-10-00050"><label>12.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Trypanosomiasis, Human African (Sleeping Sickness)&#x02014;Fact Sheet</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-27">(accessed on 27 January 2025)</date-in-citation></element-citation></ref><ref id="B13-tropicalmed-10-00050"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lindner</surname><given-names>A.K.</given-names></name>
<name><surname>Lejon</surname><given-names>V.</given-names></name>
<name><surname>Chappuis</surname><given-names>F.</given-names></name>
<name><surname>Seixas</surname><given-names>J.</given-names></name>
<name><surname>Kazumba</surname><given-names>L.</given-names></name>
<name><surname>Barrett</surname><given-names>M.P.</given-names></name>
<name><surname>Mwamba</surname><given-names>E.</given-names></name>
<name><surname>Erphas</surname><given-names>O.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Villanueva</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>New WHO Guidelines for Treatment of Gambiense Human African Trypanosomiasis Including Fexinidazole: Substantial Changes for Clinical Practice</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>e38</fpage><lpage>e46</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30612-7</pub-id></element-citation></ref><ref id="B14-tropicalmed-10-00050"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Priotto</surname><given-names>G.</given-names></name>
<name><surname>Kasparian</surname><given-names>S.</given-names></name>
<name><surname>Mutombo</surname><given-names>W.</given-names></name>
<name><surname>Ngouama</surname><given-names>D.</given-names></name>
<name><surname>Ghorashian</surname><given-names>S.</given-names></name>
<name><surname>Arnold</surname><given-names>U.</given-names></name>
<name><surname>Ghabri</surname><given-names>S.</given-names></name>
<name><surname>Baudin</surname><given-names>E.</given-names></name>
<name><surname>Buard</surname><given-names>V.</given-names></name>
<name><surname>Kazadi-Kyanza</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Nifurtimox-Eflornithine Combination Therapy for Second-Stage African Trypanosoma Brucei Gambiense Trypanosomiasis: A Multicentre, Randomised, Phase III, Non-Inferiority Trial</article-title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61117-X</pub-id><pub-id pub-id-type="pmid">19559476</pub-id>
</element-citation></ref><ref id="B15-tropicalmed-10-00050"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>V.</given-names></name>
<name><surname>Dias</surname><given-names>N.</given-names></name>
<name><surname>Paiva</surname><given-names>T.</given-names></name>
<name><surname>Hagstr&#x000f6;m-Bex</surname><given-names>L.</given-names></name>
<name><surname>Nitz</surname><given-names>N.</given-names></name>
<name><surname>Pratesi</surname><given-names>R.</given-names></name>
<name><surname>Hecht</surname><given-names>M.</given-names></name>
</person-group><article-title>Current Trends in the Pharmacological Management of Chagas Disease</article-title><source>Int. J. Parasitol. Drugs Drug Resist.</source><year>2020</year><volume>12</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2019.11.004</pub-id><pub-id pub-id-type="pmid">31862616</pub-id>
</element-citation></ref><ref id="B16-tropicalmed-10-00050"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swett</surname><given-names>M.C.</given-names></name>
<name><surname>Rayes</surname><given-names>D.L.</given-names></name>
<name><surname>Campos</surname><given-names>S.V.</given-names></name>
<name><surname>Kumar</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Chagas Disease: Epidemiology, Diagnosis, and Treatment</article-title><source>Curr. Cardiol. Rep.</source><year>2024</year><volume>26</volume><fpage>1105</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1007/s11886-024-02113-7</pub-id><pub-id pub-id-type="pmid">39115799</pub-id>
</element-citation></ref><ref id="B17-tropicalmed-10-00050"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Molina</surname><given-names>J.A.</given-names></name>
<name><surname>Molina</surname><given-names>I.</given-names></name>
</person-group><article-title>Chagas Disease</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>82</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31612-4</pub-id><pub-id pub-id-type="pmid">28673423</pub-id>
</element-citation></ref><ref id="B18-tropicalmed-10-00050"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rassi</surname><given-names>A.</given-names></name>
<name><surname>Rassi</surname><given-names>A.</given-names></name>
<name><surname>Marcondes de Rezende</surname><given-names>J.</given-names></name>
</person-group><article-title>American Trypanosomiasis (Chagas Disease)</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2012</year><volume>26</volume><fpage>275</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2012.03.002</pub-id><pub-id pub-id-type="pmid">22632639</pub-id>
</element-citation></ref><ref id="B19-tropicalmed-10-00050"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torchelsen</surname><given-names>F.K.V.D.S.</given-names></name>
<name><surname>Mazzeti</surname><given-names>A.L.</given-names></name>
<name><surname>Mosqueira</surname><given-names>V.C.F.</given-names></name>
</person-group><article-title>Drugs in Preclinical and Early Clinical Development for the Treatment of Chagas&#x02019;s Disease: The Current Status</article-title><source>Expert Opin. Investig. Drugs</source><year>2024</year><volume>33</volume><fpage>575</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1080/13543784.2024.2349289</pub-id></element-citation></ref><ref id="B20-tropicalmed-10-00050"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saulnier Sholler</surname><given-names>G.L.</given-names></name>
<name><surname>Brard</surname><given-names>L.</given-names></name>
<name><surname>Straub</surname><given-names>J.A.</given-names></name>
<name><surname>Dorf</surname><given-names>L.</given-names></name>
<name><surname>Illeyne</surname><given-names>S.</given-names></name>
<name><surname>Koto</surname><given-names>K.</given-names></name>
<name><surname>Kalkunte</surname><given-names>S.</given-names></name>
<name><surname>Bosenberg</surname><given-names>M.</given-names></name>
<name><surname>Ashikaga</surname><given-names>T.</given-names></name>
<name><surname>Nishi</surname><given-names>R.</given-names></name>
</person-group><article-title>Nifurtimox Induces Apoptosis of Neuroblastoma Cells In Vitro and In Vivo</article-title><source>J. Pediatr. Hematol. Oncol.</source><year>2009</year><volume>31</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1097/MPH.0b013e3181984d91</pub-id><pub-id pub-id-type="pmid">19262245</pub-id>
</element-citation></ref><ref id="B21-tropicalmed-10-00050"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saulnier Sholler</surname><given-names>G.L.</given-names></name>
<name><surname>Kalkunte</surname><given-names>S.</given-names></name>
<name><surname>Greenlaw</surname><given-names>C.</given-names></name>
<name><surname>McCarten</surname><given-names>K.</given-names></name>
<name><surname>Forman</surname><given-names>E.</given-names></name>
</person-group><article-title>Antitumor Activity of Nifurtimox Observed in a Patient With Neuroblastoma</article-title><source>J. Pediatr. Hematol. Oncol.</source><year>2006</year><volume>28</volume><fpage>693</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1097/01.mph.0000212994.56812.f2</pub-id><pub-id pub-id-type="pmid">17023833</pub-id>
</element-citation></ref><ref id="B22-tropicalmed-10-00050"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>E.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Ren</surname><given-names>H.</given-names></name>
<name><surname>Jiao</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Nifurtimox Inhibits the Progression of Neuroblastoma in Vivo</article-title><source>J. Cancer</source><year>2019</year><volume>10</volume><fpage>2194</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.7150/jca.27851</pub-id><pub-id pub-id-type="pmid">31258723</pub-id>
</element-citation></ref><ref id="B23-tropicalmed-10-00050"><label>23.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Sholler</surname><given-names>G.L.S.</given-names></name>
<name><surname>Swamy</surname><given-names>N.</given-names></name>
<name><surname>Kalkunte</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>R.K.</given-names></name>
<name><surname>Brard</surname><given-names>L.</given-names></name>
<name><surname>Kim</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Nitrofuran Compounds for the Treatment of Cancer and Angiogenesis</article-title><source>U.S. Patent</source><patent>No. 8,470,815</patent><day>25</day><month>June</month><year>2013</year></element-citation></ref><ref id="B24-tropicalmed-10-00050"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arr&#x000fa;a</surname><given-names>E.C.</given-names></name>
<name><surname>Seremeta</surname><given-names>K.P.</given-names></name>
<name><surname>Bedogni</surname><given-names>G.R.</given-names></name>
<name><surname>Okulik</surname><given-names>N.B.</given-names></name>
<name><surname>Salomon</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Nanocarriers for Effective Delivery of Benznidazole and Nifurtimox in the Treatment of Chagas Disease: A Review</article-title><source>Acta Trop.</source><year>2019</year><volume>198</volume><fpage>105080</fpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2019.105080</pub-id><pub-id pub-id-type="pmid">31299283</pub-id>
</element-citation></ref><ref id="B25-tropicalmed-10-00050"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mosqueira</surname><given-names>V.C.F.</given-names></name>
<name><surname>Mazzeti</surname><given-names>A.L.</given-names></name>
<name><surname>Bahia</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Nanomedicines against Chagas Disease</article-title><source>Applications of Nanobiotechnology for Neglected Tropical Diseases</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2021</year><fpage>169</fpage><lpage>189</lpage><isbn>978-0-12-821100-7</isbn></element-citation></ref><ref id="B26-tropicalmed-10-00050"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paulos</surname><given-names>C.</given-names></name>
<name><surname>Paredes</surname><given-names>J.</given-names></name>
<name><surname>Vasquez</surname><given-names>I.</given-names></name>
<name><surname>Thambo</surname><given-names>S.</given-names></name>
<name><surname>Arancibia</surname><given-names>A.</given-names></name>
<name><surname>Gonzalez-Martin</surname><given-names>G.</given-names></name>
</person-group><article-title>Pharmacokinetics of a Nitrofuran Compound, Nifurtimox, in Healthy Volunteers</article-title><source>Int. J. Clin. Pharmacol.</source><year>1989</year><volume>27</volume><fpage>454</fpage><lpage>457</lpage></element-citation></ref><ref id="B27-tropicalmed-10-00050"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moroni</surname><given-names>A.B.</given-names></name>
<name><surname>Mayoral</surname><given-names>E.P.</given-names></name>
<name><surname>Lionello</surname><given-names>D.F.</given-names></name>
<name><surname>Vega</surname><given-names>D.R.</given-names></name>
<name><surname>Kaufman</surname><given-names>T.S.</given-names></name>
<name><surname>Calvo</surname><given-names>N.L.</given-names></name>
</person-group><article-title>Solid-State Properties of Nifurtimox. Preparation, Analytical Characterization, and Stability of an Amorphous Phase</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2023</year><volume>184</volume><fpage>25</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2023.01.008</pub-id><pub-id pub-id-type="pmid">36681284</pub-id>
</element-citation></ref><ref id="B28-tropicalmed-10-00050"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stass</surname><given-names>H.</given-names></name>
<name><surname>Just</surname><given-names>S.</given-names></name>
<name><surname>Weimann</surname><given-names>B.</given-names></name>
<name><surname>Ince</surname><given-names>I.</given-names></name>
<name><surname>Willmann</surname><given-names>S.</given-names></name>
<name><surname>Feleder</surname><given-names>E.</given-names></name>
<name><surname>Freitas</surname><given-names>C.</given-names></name>
<name><surname>Yerino</surname><given-names>G.</given-names></name>
<name><surname>M&#x000fc;nster</surname><given-names>U.</given-names></name>
</person-group><article-title>Clinical Investigation of the Biopharmaceutical Characteristics of Nifurtimox Tablets&#x02014;Implications for Quality Control and Application</article-title><source>Eur. J. Pharm. Sci.</source><year>2021</year><volume>166</volume><fpage>105940</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2021.105940</pub-id><pub-id pub-id-type="pmid">34265407</pub-id>
</element-citation></ref><ref id="B29-tropicalmed-10-00050"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mazzeti</surname><given-names>A.L.</given-names></name>
<name><surname>Oliveira</surname><given-names>L.T.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>K.R.</given-names></name>
<name><surname>Schaun</surname><given-names>G.C.</given-names></name>
<name><surname>Mosqueira</surname><given-names>V.C.F.</given-names></name>
<name><surname>Bahia</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Benznidazole Self-Emulsifying Delivery System: A Novel Alternative Dosage Form for Chagas Disease Treatment</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>145</volume><fpage>105234</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105234</pub-id><pub-id pub-id-type="pmid">31978590</pub-id>
</element-citation></ref><ref id="B30-tropicalmed-10-00050"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porter</surname><given-names>C.J.H.</given-names></name>
<name><surname>Pouton</surname><given-names>C.W.</given-names></name>
<name><surname>Cuine</surname><given-names>J.F.</given-names></name>
<name><surname>Charman</surname><given-names>W.N.</given-names></name>
</person-group><article-title>Enhancing Intestinal Drug Solubilisation Using Lipid-Based Delivery Systems</article-title><source>Adv. Drug Deliv. Rev.</source><year>2008</year><volume>60</volume><fpage>673</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.10.014</pub-id><pub-id pub-id-type="pmid">18155801</pub-id>
</element-citation></ref><ref id="B31-tropicalmed-10-00050"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Worku</surname><given-names>Z.A.</given-names></name>
<name><surname>Van den Mooter</surname><given-names>G.</given-names></name>
</person-group><article-title>Oral Formulation Strategies to Improve Solubility of Poorly Water-Soluble Drugs</article-title><source>Expert Opin. Drug Deliv.</source><year>2011</year><volume>8</volume><fpage>1361</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1517/17425247.2011.606808</pub-id><pub-id pub-id-type="pmid">21810062</pub-id>
</element-citation></ref><ref id="B32-tropicalmed-10-00050"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Driscoll</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Lipid-Based Formulations for Intestinal Lymphatic Delivery</article-title><source>Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci.</source><year>2002</year><volume>15</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/S0928-0987(02)00051-9</pub-id></element-citation></ref><ref id="B33-tropicalmed-10-00050"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mazzeti</surname><given-names>A.L.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>K.R.</given-names></name>
<name><surname>Boasqu&#x000ed;vis</surname><given-names>P.F.</given-names></name>
<name><surname>Barbosa</surname><given-names>J.</given-names></name>
<name><surname>Pereira</surname><given-names>B.G.</given-names></name>
<name><surname>Soeiro</surname><given-names>M.D.N.C.</given-names></name>
<name><surname>Mosqueira</surname><given-names>V.C.F.</given-names></name>
<name><surname>Bahia</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Poly-&#x003b5;-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1126</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15041126</pub-id><pub-id pub-id-type="pmid">37111612</pub-id>
</element-citation></ref><ref id="B34-tropicalmed-10-00050"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dash</surname><given-names>T.K.</given-names></name>
<name><surname>Konkimalla</surname><given-names>V.B.</given-names></name>
</person-group><article-title>Poly-&#x003b5;-Caprolactone Based Formulations for Drug Delivery and Tissue Engineering: A Review</article-title><source>J. Control. Release</source><year>2012</year><volume>158</volume><fpage>15</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2011.09.064</pub-id><pub-id pub-id-type="pmid">21963774</pub-id>
</element-citation></ref><ref id="B35-tropicalmed-10-00050"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mondal</surname><given-names>D.</given-names></name>
<name><surname>Griffith</surname><given-names>M.</given-names></name>
<name><surname>Venkatraman</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Polycaprolactone-Based Biomaterials for Tissue Engineering and Drug Delivery: Current Scenario and Challenges</article-title><source>Int. J. Polym. Mater. Polym. Biomater.</source><year>2016</year><volume>65</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1080/00914037.2015.1103241</pub-id></element-citation></ref><ref id="B36-tropicalmed-10-00050"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malikmammadov</surname><given-names>E.</given-names></name>
<name><surname>Tanir</surname><given-names>T.E.</given-names></name>
<name><surname>Kiziltay</surname><given-names>A.</given-names></name>
<name><surname>Hasirci</surname><given-names>V.</given-names></name>
<name><surname>Hasirci</surname><given-names>N.</given-names></name>
</person-group><article-title>PCL and PCL-Based Materials in Biomedical Applications</article-title><source>J. Biomater. Sci. Polym. Ed.</source><year>2018</year><volume>29</volume><fpage>863</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1080/09205063.2017.1394711</pub-id><pub-id pub-id-type="pmid">29053081</pub-id>
</element-citation></ref><ref id="B37-tropicalmed-10-00050"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>OECD</collab>
</person-group><source>Test No. 123: Partition Coefficient (1-Octanol/Water): Slow-Stirring Method</source><comment>OECD Guidelines for the Testing of Chemicals, Section 1</comment><publisher-name>OECD Publishing</publisher-name><publisher-loc>Paris, France</publisher-loc><year>2022</year><pub-id pub-id-type="doi">10.1787/9789264015845-en</pub-id></element-citation></ref><ref id="B38-tropicalmed-10-00050"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sp&#x000f3;sito</surname><given-names>P.&#x000c1;.F.</given-names></name>
<name><surname>Mazzeti Silva</surname><given-names>A.L.</given-names></name>
<name><surname>de Oliveira Faria</surname><given-names>C.</given-names></name>
<name><surname>Urbina</surname><given-names>J.A.</given-names></name>
<name><surname>Pound-Lana</surname><given-names>G.</given-names></name>
<name><surname>Bahia</surname><given-names>M.T.</given-names></name>
<name><surname>Mosqueira</surname><given-names>V.C.F.</given-names></name>
</person-group><article-title>Ravuconazole Self-Emulsifying Delivery System: In Vitro Activity against Trypanosoma Cruzi Amastigotes and in Vivo Toxicity</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>3785</fpage><lpage>3799</lpage><pub-id pub-id-type="doi">10.2147/IJN.S133708</pub-id></element-citation></ref><ref id="B39-tropicalmed-10-00050"><label>39.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>United States</collab>
</person-group><source>Pharmacopeia Convention General Information</source><publisher-name>USP</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2006</year><volume>Volume 1</volume></element-citation></ref><ref id="B40-tropicalmed-10-00050"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>L.T.</given-names></name>
<name><surname>Castanheira</surname><given-names>R.G.</given-names></name>
<name><surname>Vilela</surname><given-names>J.M.C.</given-names></name>
<name><surname>Andrade</surname><given-names>M.S.</given-names></name>
<name><surname>De Oliveira</surname><given-names>M.A.</given-names></name>
<name><surname>Mosqueira</surname><given-names>V.C.F.</given-names></name>
</person-group><article-title>Impact of Non-Ionic Surfactants on Release Kinetics, Toxicity and Colloidal Characteristics of Benznidazole Self-Emulsifying Delivery System Evidenced by Flow Field-Flow Fractionation</article-title><source>J. Chromatogr. A</source><year>2025</year><volume>1740</volume><fpage>465565</fpage><pub-id pub-id-type="doi">10.1016/j.chroma.2024.465565</pub-id><pub-id pub-id-type="pmid">39657427</pub-id>
</element-citation></ref><ref id="B41-tropicalmed-10-00050"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Feng</surname><given-names>N.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
</person-group><article-title>Preparation and Evaluation of Self-Microemulsifying Drug Delivery System of Oridonin</article-title><source>Int. J. Pharm.</source><year>2008</year><volume>355</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2007.12.026</pub-id><pub-id pub-id-type="pmid">18242895</pub-id>
</element-citation></ref><ref id="B42-tropicalmed-10-00050"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Huo</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Zou</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Yao</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>S.</given-names></name>
</person-group><article-title>DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9185-1</pub-id><pub-id pub-id-type="pmid">20373062</pub-id>
</element-citation></ref><ref id="B43-tropicalmed-10-00050"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Riss</surname><given-names>T.L.</given-names></name>
<name><surname>Moravec</surname><given-names>R.A.</given-names></name>
<name><surname>Niles</surname><given-names>A.L.</given-names></name>
<name><surname>Duellman</surname><given-names>S.</given-names></name>
<name><surname>Benink</surname><given-names>H.A.</given-names></name>
<name><surname>Worzella</surname><given-names>T.J.</given-names></name>
<name><surname>Minor</surname><given-names>L.</given-names></name>
</person-group><article-title>Cell Viability Assays</article-title><source>Assay Guidance Manual</source><person-group person-group-type="editor">
<name><surname>Sittampalam</surname><given-names>G.S.</given-names></name>
<name><surname>Coussens</surname><given-names>N.P.</given-names></name>
<name><surname>Brimacombe</surname><given-names>K.</given-names></name>
<name><surname>Grossman</surname><given-names>A.</given-names></name>
<name><surname>Arkin</surname><given-names>M.</given-names></name>
<name><surname>Auld</surname><given-names>D.</given-names></name>
<name><surname>Austin</surname><given-names>C.</given-names></name>
<name><surname>Baell</surname><given-names>J.</given-names></name>
<name><surname>Bejcek</surname><given-names>B.</given-names></name>
<name><surname>Caaveiro</surname><given-names>J.M.M.</given-names></name>
<etal/>
</person-group><publisher-name>Eli Lilly &#x00026; Company and the National Center for Advancing Translational Sciences</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2004</year></element-citation></ref><ref id="B44-tropicalmed-10-00050"><label>44.</label><element-citation publication-type="book"><article-title>ISO Part 5: Tests for in Vitro Cytotoxicity&#x02014;ISO 10993-5</article-title><source>Biological Evaluation of Medical Devices&#x02014;ISO 10993</source><publisher-name>International Organization for Standardization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2009</year></element-citation></ref><ref id="B45-tropicalmed-10-00050"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diniz</surname><given-names>L.d.F.</given-names></name>
<name><surname>Mazzeti</surname><given-names>A.L.</given-names></name>
<name><surname>Caldas</surname><given-names>I.S.</given-names></name>
<name><surname>Ribeiro</surname><given-names>I.</given-names></name>
<name><surname>Bahia</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant <italic toggle="yes">Trypanosoma Cruzi</italic> Strain in Mice</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e00401-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.00401-18</pub-id><pub-id pub-id-type="pmid">29555633</pub-id>
</element-citation></ref><ref id="B46-tropicalmed-10-00050"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filardi</surname><given-names>L.S.</given-names></name>
<name><surname>Brener</surname><given-names>Z.</given-names></name>
</person-group><article-title>Susceptibility and Natural Resistance of Trypanosoma Cruzi Strains to Drugs Used Clinically in Chagas Disease</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1987</year><volume>81</volume><fpage>755</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(87)90020-4</pub-id><pub-id pub-id-type="pmid">3130683</pub-id>
</element-citation></ref><ref id="B47-tropicalmed-10-00050"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caldas</surname><given-names>S.</given-names></name>
<name><surname>Santos</surname><given-names>F.M.</given-names></name>
<name><surname>Lana</surname><given-names>M.d.</given-names></name>
<name><surname>Diniz</surname><given-names>L.F.</given-names></name>
<name><surname>Machado-Coelho</surname><given-names>G.L.L.</given-names></name>
<name><surname>Veloso</surname><given-names>V.M.</given-names></name>
<name><surname>Bahia</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Trypanosoma Cruzi: Acute and Long-Term Infection in the Vertebrate Host Can Modify the Response to Benznidazole</article-title><source>Exp. Parasitol.</source><year>2008</year><volume>118</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2007.08.016</pub-id><pub-id pub-id-type="pmid">17945216</pub-id>
</element-citation></ref><ref id="B48-tropicalmed-10-00050"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brener</surname><given-names>Z.</given-names></name>
</person-group><article-title>Therapeutic Activity and Criterion of Cure on Mice Experimentally Infected with Trypanosoma Cruzi</article-title><source>Rev. Inst. Med. Trop. Sao Paulo</source><year>1962</year><volume>4</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">14015230</pub-id>
</element-citation></ref><ref id="B49-tropicalmed-10-00050"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cummings</surname><given-names>K.L.</given-names></name>
<name><surname>Tarleton</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Rapid Quantitation of Trypanosoma Cruzi in Host Tissue by Real-Time PCR</article-title><source>Mol. Biochem. Parasitol.</source><year>2003</year><volume>129</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/S0166-6851(03)00093-8</pub-id><pub-id pub-id-type="pmid">12798506</pub-id>
</element-citation></ref><ref id="B50-tropicalmed-10-00050"><label>50.</label><element-citation publication-type="book"><source>ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Note for Guidance on Validation of Analytical Procedures: Text and Methodology (CPMP/ICH/381/95)</source><publisher-name>European Medicines Agency</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>1995</year></element-citation></ref><ref id="B51-tropicalmed-10-00050"><label>51.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Pharmacopoeia Library</article-title><comment>Available online: <ext-link xlink:href="https://apps.who.int/phint/en/p/docf/" ext-link-type="uri">https://apps.who.int/phint/en/p/docf/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-23">(accessed on 23 July 2020)</date-in-citation></element-citation></ref><ref id="B52-tropicalmed-10-00050"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasim</surname><given-names>N.A.</given-names></name>
<name><surname>Whitehouse</surname><given-names>M.</given-names></name>
<name><surname>Ramachandran</surname><given-names>C.</given-names></name>
<name><surname>Bermejo</surname><given-names>M.</given-names></name>
<name><surname>Lennern&#x000e4;s</surname><given-names>H.</given-names></name>
<name><surname>Hussain</surname><given-names>A.S.</given-names></name>
<name><surname>Junginger</surname><given-names>H.E.</given-names></name>
<name><surname>Stavchansky</surname><given-names>S.A.</given-names></name>
<name><surname>Midha</surname><given-names>K.K.</given-names></name>
<name><surname>Shah</surname><given-names>V.P.</given-names></name>
<etal/>
</person-group><article-title>Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification</article-title><source>Mol. Pharm.</source><year>2004</year><volume>1</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1021/mp034006h</pub-id><pub-id pub-id-type="pmid">15832504</pub-id>
</element-citation></ref><ref id="B53-tropicalmed-10-00050"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Chavhan</surname><given-names>S.</given-names></name>
<name><surname>Sawant</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Self-Nanoemulsifying Drug Delivery System for Adefovir Dipivoxil: Design, Characterization, in Vitro and Ex Vivo Evaluation</article-title><source>Colloids Surf. Physicochem. Eng. Asp.</source><year>2011</year><volume>392</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfa.2011.09.048</pub-id></element-citation></ref><ref id="B54-tropicalmed-10-00050"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de la Concepci&#x000f3;n Foces-Foces</surname><given-names>M.</given-names></name>
<name><surname>Cano</surname><given-names>F.H.</given-names></name>
<name><surname>Claramunt</surname><given-names>R.M.</given-names></name>
<name><surname>Fruchier</surname><given-names>A.</given-names></name>
<name><surname>Elguero</surname><given-names>J.</given-names></name>
</person-group><article-title>Molecular Structure in the Solid State (X-Ray Diffraction) and in Solution (<sup>1</sup>H and <sup>13</sup>C NMR) of Nifurtimox and Two pyrazol-1-Yl Analogs</article-title><source>Bull. Soci&#x000e9;t&#x000e9;s Chim. Belg.</source><year>1988</year><volume>97</volume><fpage>1055</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1002/bscb.19880971131</pub-id></element-citation></ref><ref id="B55-tropicalmed-10-00050"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holzer</surname><given-names>W.</given-names></name>
</person-group><article-title>Determination of the Stereochemistry of Chemotherapeutics Derived from 5-Nitrofurfural: NOE Difference Spectroscopy as a Simple and Reliable Method</article-title><source>Arch. Pharm.</source><year>1992</year><volume>325</volume><fpage>769</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1002/ardp.19923251205</pub-id></element-citation></ref><ref id="B56-tropicalmed-10-00050"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marin-Neto</surname><given-names>J.A.</given-names></name>
<name><surname>Rassi</surname><given-names>A.</given-names></name>
<name><surname>Oliveira</surname><given-names>G.M.M.</given-names></name>
<name><surname>Correia</surname><given-names>L.C.L.</given-names></name>
<name><surname>Ramos</surname><given-names>A.N.</given-names></name>
<name><surname>Luquetti</surname><given-names>A.O.</given-names></name>
<name><surname>Hasslocher-Moreno</surname><given-names>A.M.</given-names></name>
<name><surname>Sousa</surname><given-names>A.S.D.</given-names></name>
<name><surname>Paola</surname><given-names>A.A.V.D.</given-names></name>
<name><surname>Sousa</surname><given-names>A.C.S.</given-names></name>
<etal/>
</person-group><article-title>Diretriz da SBC Sobre Diagn&#x000f3;stico e Tratamento de Pacientes Com Cardiomiopatia Da Doen&#x000e7;a de Chagas&#x02014;2023</article-title><source>Arq. Bras. Cardiol.</source><year>2023</year><volume>120</volume><fpage>e20230269</fpage><pub-id pub-id-type="doi">10.36660/abc.20230269</pub-id><pub-id pub-id-type="pmid">37377258</pub-id>
</element-citation></ref><ref id="B57-tropicalmed-10-00050"><label>57.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rowe</surname><given-names>R.C.</given-names></name>
<name><surname>Sheskey</surname><given-names>P.J.</given-names></name>
<name><surname>Owen</surname><given-names>S.C.</given-names></name>
</person-group><source>Handbook of Pharmaceutical Excipients</source><edition>6th ed.</edition><person-group person-group-type="editor">
<name><surname>Rowe</surname><given-names>R.C.</given-names></name>
<name><surname>Sheskey</surname><given-names>P.</given-names></name>
<name><surname>Quinn</surname><given-names>M.</given-names></name>
<collab>American Pharmacists Association</collab>
</person-group><publisher-name>APhA/Pharmaceutical Press</publisher-name><publisher-loc>Chicago, IL, USA</publisher-loc><year>2009</year><isbn>978-1-58212-135-2</isbn></element-citation></ref><ref id="B58-tropicalmed-10-00050"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cherniakov</surname><given-names>I.</given-names></name>
<name><surname>Domb</surname><given-names>A.J.</given-names></name>
<name><surname>Hoffman</surname><given-names>A.</given-names></name>
</person-group><article-title>Self-Nano-Emulsifying Drug Delivery Systems: An Update of the Biopharmaceutical Aspects</article-title><source>Expert Opin. Drug Deliv.</source><year>2015</year><volume>12</volume><fpage>1121</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1517/17425247.2015.999038</pub-id><pub-id pub-id-type="pmid">25556987</pub-id>
</element-citation></ref><ref id="B59-tropicalmed-10-00050"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savla</surname><given-names>R.</given-names></name>
<name><surname>Browne</surname><given-names>J.</given-names></name>
<name><surname>Plassat</surname><given-names>V.</given-names></name>
<name><surname>Wasan</surname><given-names>K.M.</given-names></name>
<name><surname>Wasan</surname><given-names>E.K.</given-names></name>
</person-group><article-title>Review and Analysis of FDA Approved Drugs Using Lipid-Based Formulations</article-title><source>Drug Dev. Ind. Pharm.</source><year>2017</year><volume>43</volume><fpage>1743</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1080/03639045.2017.1342654</pub-id><pub-id pub-id-type="pmid">28673096</pub-id>
</element-citation></ref><ref id="B60-tropicalmed-10-00050"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kollipara</surname><given-names>S.</given-names></name>
<name><surname>Gandhi</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Pharmacokinetic Aspects and in Vitro&#x02013;in Vivo Correlation Potential for Lipid-Based Formulations</article-title><source>Acta Pharm. Sin. B</source><year>2014</year><volume>4</volume><fpage>333</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2014.09.001</pub-id><pub-id pub-id-type="pmid">26579403</pub-id>
</element-citation></ref><ref id="B61-tropicalmed-10-00050"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stass</surname><given-names>H.</given-names></name>
<name><surname>Feleder</surname><given-names>E.</given-names></name>
<name><surname>Garcia-Bournissen</surname><given-names>F.</given-names></name>
<name><surname>Nagelschmitz</surname><given-names>J.</given-names></name>
<name><surname>Weimann</surname><given-names>B.</given-names></name>
<name><surname>Yerino</surname><given-names>G.</given-names></name>
<name><surname>Altcheh</surname><given-names>J.</given-names></name>
</person-group><article-title>Biopharmaceutical Characteristics of Nifurtimox Tablets for Age- and Body Weight-Adjusted Dosing in Patients With Chagas Disease</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2021</year><volume>10</volume><fpage>542</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1002/cpdd.871</pub-id><pub-id pub-id-type="pmid">33029953</pub-id>
</element-citation></ref><ref id="B62-tropicalmed-10-00050"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kratz</surname><given-names>J.M.</given-names></name>
<name><surname>Garcia Bournissen</surname><given-names>F.</given-names></name>
<name><surname>Forsyth</surname><given-names>C.J.</given-names></name>
<name><surname>Sosa-Estani</surname><given-names>S.</given-names></name>
</person-group><article-title>Clinical and Pharmacological Profile of Benznidazole for Treatment of Chagas Disease</article-title><source>Expert Rev. Clin. Pharmacol.</source><year>2018</year><volume>11</volume><fpage>943</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1080/17512433.2018.1509704</pub-id><pub-id pub-id-type="pmid">30111183</pub-id>
</element-citation></ref><ref id="B63-tropicalmed-10-00050"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000e1;zquez</surname><given-names>C.</given-names></name>
<name><surname>Garc&#x000ed;a-V&#x000e1;zquez</surname><given-names>E.</given-names></name>
<name><surname>Carrilero</surname><given-names>B.</given-names></name>
<name><surname>Sim&#x000f3;n</surname><given-names>M.</given-names></name>
<name><surname>Franco</surname><given-names>F.</given-names></name>
<name><surname>Iborra</surname><given-names>M.A.</given-names></name>
<name><surname>Gil-Gallardo</surname><given-names>L.J.</given-names></name>
<name><surname>Segovia</surname><given-names>M.</given-names></name>
</person-group><article-title>Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole</article-title><source>Rev. Soc. Bras. Med. Trop.</source><year>2023</year><volume>56</volume><fpage>e0384-2022</fpage><pub-id pub-id-type="doi">10.1590/0037-8682-0384-2022</pub-id><pub-id pub-id-type="pmid">36700605</pub-id>
</element-citation></ref><ref id="B64-tropicalmed-10-00050"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novaes</surname><given-names>R.D.</given-names></name>
<name><surname>Santos</surname><given-names>E.C.</given-names></name>
<name><surname>Cupertino</surname><given-names>M.C.</given-names></name>
<name><surname>Bastos</surname><given-names>D.S.S.</given-names></name>
<name><surname>Oliveira</surname><given-names>J.M.</given-names></name>
<name><surname>Carvalho</surname><given-names>T.V.</given-names></name>
<name><surname>Neves</surname><given-names>M.M.</given-names></name>
<name><surname>Oliveira</surname><given-names>L.L.</given-names></name>
<name><surname>Talvani</surname><given-names>A.</given-names></name>
</person-group><article-title>Trypanosoma Cruzi Infection and Benznidazole Therapy Independently Stimulate Oxidative Status and Structural Pathological Remodeling of the Liver Tissue in Mice</article-title><source>Parasitol. Res.</source><year>2015</year><volume>114</volume><fpage>2873</fpage><lpage>2881</lpage><pub-id pub-id-type="doi">10.1007/s00436-015-4488-x</pub-id><pub-id pub-id-type="pmid">25912691</pub-id>
</element-citation></ref><ref id="B65-tropicalmed-10-00050"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>W.D.B.</given-names></name>
<name><surname>Weber</surname><given-names>A.</given-names></name>
<name><surname>Ferri</surname><given-names>J.</given-names></name>
<name><surname>Etges</surname><given-names>A.</given-names></name>
<name><surname>Neto</surname><given-names>P.I.</given-names></name>
<name><surname>Pereira</surname><given-names>F.D.A.D.S.</given-names></name>
<name><surname>Heitz</surname><given-names>C.</given-names></name>
</person-group><article-title>An Analysis of the Biocompatibility, Cytotoxicity, and Bone Conductivity of Polycaprolactone: An In Vivo Study</article-title><source>Polymers</source><year>2024</year><volume>16</volume><elocation-id>2271</elocation-id><pub-id pub-id-type="doi">10.3390/polym16162271</pub-id><pub-id pub-id-type="pmid">39204491</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="tropicalmed-10-00050-f001"><label>Figure 1</label><caption><p>Chemical structures of nitro-heterocyclic compounds, nifurtimox and benznidazole, both recommended by the World Health Organization for treating Chagas disease.</p></caption><graphic xlink:href="tropicalmed-10-00050-g001" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f002"><label>Figure 2</label><caption><p>Experimental design of three treatment protocols: I (20 days), II (40 days), and III (mixed: oral plus implant). Non-infected and infected control groups are shown alongside groups receiving the different treatment regimens, including the oral administration of free nifurtimox (NFX), the NFX-SEDDS formulations, and the NFX-PCL implants. The treatment durations and evaluation time points for the mortality, parasitemia, and qPCR analyses are indicated. Blue lines represent the total duration of the experiment, brown and yellow lines indicate the NFX treatment duration, and red lines the time duration of parasitemia monitoring. FBE: fresh blood examination. qPCR: Polymerase Chain Reaction.</p></caption><graphic xlink:href="tropicalmed-10-00050-g002" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f003"><label>Figure 3</label><caption><p>Comparative release profiles of nifurtimox from the SEDDS (solid lines) and the coarse suspension (dashed lines) in simulated gastric fluid (black) and intestinal fluid (blue) at 37 &#x000b0;C. The experiment was conducted under sink conditions using a direct dialysis method, and each time point represents the mean values and standard deviations (n = 3).</p></caption><graphic xlink:href="tropicalmed-10-00050-g003" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f004"><label>Figure 4</label><caption><p>X-ray diffractogram analysis. (<bold>A</bold>) Overlay of X-ray diffractograms: NFX-PCL (in black) and nifurtimox (in red). (<bold>B</bold>) Overlay of X-ray diffractograms: NFX-PCL implant (in black) and blank-PCL implant (without the drug) (in blue). The red arrows show the peaks that cannot be attributed to the pure drug (in (<bold>A</bold>)) but can be attributed to the diffraction profile of the implant without NFX (in (<bold>B</bold>)).</p></caption><graphic xlink:href="tropicalmed-10-00050-g004" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f005"><label>Figure 5</label><caption><p>Scanning electron micrographs of nifurtimox: (<bold>A</bold>) magnification of 65&#x000d7;; (<bold>B</bold>) magnification of 220&#x000d7;; (<bold>C</bold>) magnification of 240&#x000d7;; (<bold>D</bold>) magnification of 270&#x000d7;; and (<bold>E</bold>) magnification of 540&#x000d7;.</p></caption><graphic xlink:href="tropicalmed-10-00050-g005" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f006"><label>Figure 6</label><caption><p>Differential Scanning Calorimetry (DSC) curve for pure nifurtimox (blue), the poly-&#x003b5;-caprolactone polymer implant without the drug (blank-PCL) (red), and the nifurtimox&#x02013;PCL implant (NFX-PCL).</p></caption><graphic xlink:href="tropicalmed-10-00050-g006" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f007"><label>Figure 7</label><caption><p>Thermo-optical analysis of pure nifurtimox crystal. (<bold>A</bold>) 25 &#x000b0;C, (<bold>B</bold>) 179.5 &#x000b0;C, (<bold>C</bold>) 180.5 &#x000b0;C, and (<bold>D</bold>) 181.5 &#x000b0;C. The images were captured using a Leica C Plan 10&#x000d7; objective lens, providing a total magnification of 100&#x000d7;.</p></caption><graphic xlink:href="tropicalmed-10-00050-g007" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f008"><label>Figure 8</label><caption><p>Scanning electron micrographs of the PCL implant without the drug (blank-PCL): (<bold>A</bold>) magnification at 240&#x000d7;; (<bold>B</bold>) magnification at 300&#x000d7;; and (<bold>C</bold>) magnification at 440&#x000d7;. Scanning electron micrographs of the NFX-PCL implant with red arrows indicates the NFX crystals: (<bold>D</bold>) magnification at 220&#x000d7;; (<bold>E</bold>) magnification at 400&#x000d7;; and (<bold>F</bold>) magnification at 540&#x000d7;.</p></caption><graphic xlink:href="tropicalmed-10-00050-g008" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f009"><label>Figure 9</label><caption><p>Thermo-optical analysis of the physical mixture of PCL and nifurtimox. The red circles highlight nifurtimox particles that solubilized into the polymer matrix upon heating, indicating a potential physical interaction, leading to solubilization. The black circles indicate nifurtimox particles that, without direct contact with the polymer, melted at the expected temperature for the pure drug, suggesting a lack of interaction in these regions. The temperatures correspond to specific thermal stages: (<bold>A</bold>) 25 &#x000b0;C, (<bold>B</bold>) 60 &#x000b0;C, (<bold>C</bold>) 66 &#x000b0;C, (<bold>D</bold>) 155 &#x000b0;C, (<bold>E</bold>) 160 &#x000b0;C, (<bold>F</bold>) 165 &#x000b0;C, (<bold>G</bold>) 168 &#x000b0;C, (<bold>H</bold>) 172.5 &#x000b0;C, (<bold>I</bold>) 175 &#x000b0;C, (<bold>J</bold>) 179.5 &#x000b0;C, (<bold>K</bold>) 180.5 &#x000b0;C, and (<bold>L</bold>) 181.5 &#x000b0;C.</p></caption><graphic xlink:href="tropicalmed-10-00050-g009" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f010"><label>Figure 10</label><caption><p>Liver enzymes levels of treated mice. (<bold>A</bold>) Aspartate aminotransferase (AST) and (<bold>B</bold>) alanine aminotransferase (ALT) serum levels of non-infected and mice infected with the <italic toggle="yes">Trypanosoma cruzi</italic> Y strain treated for 20 or 40 days with nifurtimox (NFX), the NFX-SEDDS, or NFX-PCL implants. Samples were collected on the last day of treatment. The levels of AST and ALT in the infected and non-treated control groups were measured on the 15th day of infection. * Different compared to the non-infected control, at <italic toggle="yes">p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="tropicalmed-10-00050-g010" position="float"/></fig><fig position="float" id="tropicalmed-10-00050-f011"><label>Figure 11</label><caption><p>Schematic representation of the nifurtimox delivery systems. (<bold>A</bold>) Schematic representation of droplets of nanoemulsions formed after the self-emulsifying system (SEDDS)&#x02019;s dispersion in water in the gastrointestinal tract; (<bold>B</bold>) subcutaneous implants with nifurtimox.</p></caption><graphic xlink:href="tropicalmed-10-00050-g011" position="float"/></fig><table-wrap position="float" id="tropicalmed-10-00050-t001"><object-id pub-id-type="pii">tropicalmed-10-00050-t001_Table 1</object-id><label>Table 1</label><caption><p>Apparent solubility of nifurtimox in different solvents.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solvent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solubility (mg/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Classification *</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">N</italic>-methyl pyrrolidone</td><td align="center" valign="middle" rowspan="1" colspan="1">90.85 &#x000b1; 9.04</td><td align="center" valign="middle" rowspan="1" colspan="1">Soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acetone</td><td align="center" valign="middle" rowspan="1" colspan="1">17.27 &#x000b1; 0.28</td><td align="center" valign="middle" rowspan="1" colspan="1">Slightly soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chloroform</td><td align="center" valign="middle" rowspan="1" colspan="1">14.03 &#x000b1; 2.65</td><td align="center" valign="middle" rowspan="1" colspan="1">Slightly soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acetonitrile</td><td align="center" valign="middle" rowspan="1" colspan="1">12.57 &#x000b1; 3.48</td><td align="center" valign="middle" rowspan="1" colspan="1">Slightly soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ethyl acetate</td><td align="center" valign="middle" rowspan="1" colspan="1">11.90 &#x000b1; 0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">Slightly soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Benzyl alcohol</td><td align="center" valign="middle" rowspan="1" colspan="1">10.97 &#x000b1; 1.12</td><td align="center" valign="middle" rowspan="1" colspan="1">Slightly soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tetrahydrofuran</td><td align="center" valign="middle" rowspan="1" colspan="1">5.08 &#x000b1; 3.48</td><td align="center" valign="middle" rowspan="1" colspan="1">Slightly soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Methanol</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17 &#x000b1; 0.09</td><td align="center" valign="middle" rowspan="1" colspan="1">Poorly soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dimethylacetamide</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 &#x000b1; 0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">Very little soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ethanol</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65 &#x000b1; 0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">Very little soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">n-Octanol</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11 &#x000b1; 0.00</td><td align="center" valign="middle" rowspan="1" colspan="1">Very little soluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hexane</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001 &#x000b1; 0.00</td><td align="center" valign="middle" rowspan="1" colspan="1">Insoluble</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Phosphate-buffered saline (PBS)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04 &#x000b1; 0.00</td><td align="center" valign="middle" rowspan="1" colspan="1">Insoluble</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05 &#x000b1; 0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insoluble</td></tr></tbody></table><table-wrap-foot><fn><p>* Classification according to the International Pharmacopoeia and [<xref rid="B51-tropicalmed-10-00050" ref-type="bibr">51</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tropicalmed-10-00050-t002"><object-id pub-id-type="pii">tropicalmed-10-00050-t002_Table 2</object-id><label>Table 2</label><caption><p>Physicochemical characterization and stability of SEDDS droplets after self-emulsification.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solvent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Blank-SEDDS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NFX-SEDDS</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NFX visual precipitation</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">no ppt</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Droplet size (nm)</td><td align="center" valign="middle" rowspan="1" colspan="1">282.7 &#x000b1; 13.0</td><td align="center" valign="middle" rowspan="1" colspan="1">612.57 &#x000b1; 8.53</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Polydispersity index (PdI)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.498</td><td align="center" valign="middle" rowspan="1" colspan="1">0.730</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Zeta potential (mV)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;46.6 &#x000b1; 1.81</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;46.0 &#x000b1; 3.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nifurtimox (mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.30 &#x000b1; 0.80 *</td></tr></tbody></table><table-wrap-foot><fn><p>Anhydrous SEDDS formulations were emulsified in ultra-pure water at 37 &#x000b0;C at 1:1000 dilution and stirred for 20 s. NFX = nifurtimox; NA = not applicable, ppt: NFX precipitates. * Content of NFX was determined using the HPLC method.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tropicalmed-10-00050-t003"><object-id pub-id-type="pii">tropicalmed-10-00050-t003_Table 3</object-id><label>Table 3</label><caption><p>Mathematical modeling of the benznidazole dissolution/release from the SEDDS in PBS at a pH of 6.8 and 37 &#x000b0;C.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Formulation</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin" rowspan="1">First-Order<break/><italic toggle="yes">F</italic> = 100.(1 &#x02212; <italic toggle="yes">e</italic><sup>&#x02212;<italic toggle="yes">k</italic></sup><sub>1</sub><sup>t</sup>)</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Higuchi<break/><italic toggle="yes">F</italic> = 100.<italic toggle="yes">k<sub>h</sub></italic>.<italic toggle="yes">t</italic><sup>&#x02212;0.5</sup></th><th colspan="4" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Weibull<break/><italic toggle="yes">F</italic> = 100.(1 &#x02212; <italic toggle="yes">e</italic><sup>t&#x003b2;/&#x003b1;</sup>)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K</italic><sub>1</sub> (min<sup>&#x02212;1</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSD %</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">MSC</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K<sub>h</sub>
</italic>(min<sup>&#x02212;1/2</sup>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSD %</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">MSC</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">&#x003b1;</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">&#x003b2;</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">MSC</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NFX coarse suspension (SGF) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.00550 &#x000b1; 0.00093</td><td align="center" valign="middle" rowspan="1" colspan="1">16.98</td><td align="center" valign="middle" rowspan="1" colspan="1">1.986</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8720</td><td align="center" valign="middle" rowspan="1" colspan="1">4.7340 &#x000b1; 0.2914</td><td align="center" valign="middle" rowspan="1" colspan="1">6.15</td><td align="center" valign="middle" rowspan="1" colspan="1">3.512</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9760</td><td align="center" valign="middle" rowspan="1" colspan="1">22.2552</td><td align="center" valign="middle" rowspan="1" colspan="1">0.591</td><td align="center" valign="middle" rowspan="1" colspan="1">4.660</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9957</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NFX-SEDDS (SGF)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00246 &#x000b1; 0.00021</td><td align="center" valign="middle" rowspan="1" colspan="1">8.47</td><td align="center" valign="middle" rowspan="1" colspan="1">1.986</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8642</td><td align="center" valign="middle" rowspan="1" colspan="1">2.7073 &#x000b1; 0.3042</td><td align="center" valign="middle" rowspan="1" colspan="1">11.23</td><td align="center" valign="middle" rowspan="1" colspan="1">2.069</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8923</td><td align="center" valign="middle" rowspan="1" colspan="1">54.0146</td><td align="center" valign="middle" rowspan="1" colspan="1">0.611</td><td align="center" valign="middle" rowspan="1" colspan="1">1.557</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8835</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NFX coarse suspension (SIF)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00348 &#x000b1; 0.00042</td><td align="center" valign="middle" rowspan="1" colspan="1">12.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.649</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6547</td><td align="center" valign="middle" rowspan="1" colspan="1">3.7386 &#x000b1; 0.3030</td><td align="center" valign="middle" rowspan="1" colspan="1">8.10</td><td align="center" valign="middle" rowspan="1" colspan="1">2.305</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9317</td><td align="center" valign="middle" rowspan="1" colspan="1">12.7247</td><td align="center" valign="middle" rowspan="1" colspan="1">0.468</td><td align="center" valign="middle" rowspan="1" colspan="1">4.392</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9934</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NFX-SEDDS (SIF)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00267 &#x000b1; 0.00012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.052</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9608</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.7613 &#x000b1; 0.0613</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.122</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9032</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.1088</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.976</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.698</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9057</td></tr></tbody></table><table-wrap-foot><fn><p>&#x003b1; is the scale parameter that defines the time scale of the process; &#x003b2; is the shape parameter that characterizes the curve; F is the fraction dissolved; R<sup>2</sup> is the coefficient of determination; MSC: Model Selection Criterion. Values &#x0003e; 2 indicate the goodness of fit. SGF: simulated gastric fluid. SIF: simulated intestinal fluid.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tropicalmed-10-00050-t004"><object-id pub-id-type="pii">tropicalmed-10-00050-t004_Table 4</object-id><label>Table 4</label><caption><p>Cytotoxicity and anti-<italic toggle="yes">Trypanosoma cruzi</italic> activity of nifurtimox and the NFX-SEDDS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Viability</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Anti-<italic toggle="yes">T. cruzi</italic> Activity</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Selective Index (SI)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CC<sub>50</sub> (&#x000b5;M)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> (&#x000b5;M)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>90</sub> (&#x000b5;M)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nifurtimox</td><td align="center" valign="middle" rowspan="1" colspan="1">34.73 &#x000b1; 10.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72 &#x000b1; 0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">6.88 &#x000b1; 4.77</td><td align="center" valign="middle" rowspan="1" colspan="1">48.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Blank-SEDDS</td><td align="center" valign="middle" rowspan="1" colspan="1">39.21 &#x000b1; 9.03</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NFX-SEDDS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.86 &#x000b1; 9.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.37 &#x000b1; 1.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66</td></tr></tbody></table><table-wrap-foot><fn><p>CC<sub>50</sub> = cytotoxic concentration for 50% of the H9c2 cells. IC<sub>50</sub> concentration inhibits 50% of the <italic toggle="yes">T. cruzi</italic> amastigotes. SI = CC<sub>50</sub>/IC<sub>50</sub>. The NFX, NFX-SEDDS, and blank-SEDDS were tested in H9c2 cells to determine cytotoxic concentration for 96 h, and for 72 h in H9c2 cells infected with <italic toggle="yes">Trypanosoma cruzi</italic> Y strain to determine activity and inhibitory concentration.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tropicalmed-10-00050-t005"><object-id pub-id-type="pii">tropicalmed-10-00050-t005_Table 5</object-id><label>Table 5</label><caption><p>Effects of nifurtimox, the NFX-SEDDS, and the NFX-PCL implants in different treatment regimens on the course of the mice&#x02019;s infection with the Y strain of <italic toggle="yes">Trypanosoma cruzi</italic>
<sup>1</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dosage Form</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Groups/Protocol</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment<break/>Duration (Days)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parasitemia Clearance/(Days of Treatment)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Negative Results&#x02014;FBE and PCR/n&#x000b0; Animals <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Surviving/Total Animal</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Non-infected control</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">6/6 (100%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6/6 (100%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Infected control</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7&#x000a0;&#x000a0;&#x000a0;ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SEDDS</td><td align="center" valign="middle" rowspan="1" colspan="1">Infected treated&#x02014;blank-SEDDS</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7&#x000a0;&#x000a0;&#x000a0;ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Implant</td><td align="center" valign="middle" rowspan="1" colspan="1">Infected treated&#x02014;blank-PCL implants</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7&#x000a0;&#x000a0;&#x000a0;ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Free</td><td align="center" valign="middle" rowspan="1" colspan="1">Oral NFX 50 mg/kg/day</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">7/7<break/>(1.43 &#x000b1; 0.79)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/7 (14.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/7 (14%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Free</td><td align="center" valign="middle" rowspan="1" colspan="1">Oral NFX 50 mg/kg/day</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">7/7<break/>(1.71 &#x000b1; 0.49)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/7 (42.9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7/7 (100%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SEDDS</td><td align="center" valign="middle" rowspan="1" colspan="1">Oral NFX-SEDDS 50 mg/kg/day</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">7/7<break/>(1.71 &#x000b1; 0.75)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/7 (28.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7/7 (100%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Implant</td><td align="center" valign="middle" rowspan="1" colspan="1">25 mg NFX + 50 mg PCL</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">6/6<break/>(1.67 &#x000b1; 0.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/6 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6/6 (100%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Implant</td><td align="center" valign="middle" rowspan="1" colspan="1">25 mg NFX + 75 mg PCL</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">7/7<break/>(2.00 &#x000b1; 1.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/7 (0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7/7 (100%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Implant</td><td align="center" valign="middle" rowspan="1" colspan="1">50 mg NFX + 75 mg PCL</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">5/5<break/>(1.20 &#x000b1; 0.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/5 (40%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5/5 (100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Free oral + Implant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral NFX 50 mg/kg/day, 10 days + <break/>(37.5 mg NFX + 75 mg PCL), 30 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/5<break/>(2.00 &#x000b1; 1.00)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/5 (20%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/5 (100%)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Swiss mice (18 to 22 g) were inoculated with 5 &#x000d7; 10<sup>3</sup> trypomastigotes from the <italic toggle="yes">Trypanosoma cruzi</italic> Y strain. The treatment started 4 days after infection and continued for 20 or 40 days. <sup>2</sup> FBE (fresh blood examination) before and after immunosuppression using cyclophosphamide. PCR (Polymerase Chain Reaction) assays were performed 30 and 180 days after the treatment. NFX: nifurtimox. PCL: poly-&#x00190;-caprolactone.</p></fn></table-wrap-foot></table-wrap></floats-group></article>